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ABSTRACT 
 
 A tumor is a heterogeneous combination of proliferating tumor cells, infiltrating 
immune cells and stromal components along with a variety of associated host tissue cells, 
collectively termed the tumor microenvironment (TME). The constituents of the TME 
and their interaction with the host organ shape and define the properties of tumors and 
contribute towards the acquisition of hallmark traits such as hypoxia. Hypoxia imparts 
resistance to cancer from chemotherapy and radiotherapy due to the decreased production 
of reactive oxygen species and also promotes angiogenesis, malignant progression and 
metastasis. It also provides a powerful physiological stimulus that can be exploited as a 
tumor-specific condition, allowing for the rational design of anticancer hypoxia-activated 
pro-drugs (HAP). Accurate evaluation of tumor oxygenation in response to therapeutics 
interventions at various stages of growth should provide a better understanding of tumor 
response to therapy, potentially allowing therapy to be tailored to individual 
characteristics. The primary goal of this research was to investigate the utility of 
prospective identification of hypoxic tumors, by two different Magnetic Resonance 
Imaging (MRI) based oximetry approaches, in successful treatment with hypoxia 
activated therapy. In the present study, I report the utility of these two techniques 1) 
PISTOL (Proton Imaging of Siloxanes to map Tissue Oxygenation Levels) and 2) use of 
a hypoxia binding T1 contrast agent GdDO3NI in reporting the modulations of hypoxia 
pre and post hypoxia activated therapies in pre-clinical models of cancer. I have 
performed these studies in non-small cell lung cancer (NSCLC) and epidermoid 
carcinoma (NCI-H1975 and A431 cell lines, respectively) as well as in patient derived 
ii 
 
xenograft models of NSCLC. Both the oximetry techniques have the potential to 
differentiate between normoxic and hypoxic regions of the tumor and reveal both 
baseline heterogeneity and differential response to therapeutic intervention. The response 
of the tumor models to therapeutic interventions indicates that, in conjunction with pO2, 
other factors such as tumor perfusion (essential for delivering HAPs) and relative 
expression of nitroreductases (essential for activating HAPs) may play an important role. 
The long term goal of the proposed research is the clinical translation of both the MRI 
techniques and aiding the design and development of personalized therapy (e.g. patient 
stratification for novel hypoxia activated pro-drugs) particularly for cancer. 
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CHAPTER 1 
INTRODUCTION  
1.1 Tumor Microenvironment 
Cancer is the leading cause of death in the world and years of research has brought 
into light the complexity of the tumors and their transformations [1]. Cancer is a 
collective organization of malignant tumor cells and non-malignant tumor promoting 
cells. Together these constituents form the tumor microenvironment which differs 
significantly from the surrounding host tissue as it contains several modified cellular and 
molecular signatures [2-4].  These signatures or “hallmarks” [5] define the properties of a 
tumor and distinguish it from the host both morphologically and functionally (figure 1.1). 
The tumor microenvironment is a heterogeneous combination of proliferating malignant 
cells, infiltrating inflammatory cells, cancer associate fibroblast cells, endothelial cells, 
pericytes, adipocytes, extracellular matrix. The interaction of these components shapes 
and defines the pathophysiology of malignant tumors and contribute at varying degree 
towards the acquisition of hallmark traits such as decreased apoptotic potential, 
angiogenesis, resistance to treatment, metastasis, invasion and hypoxia [3-15]. The 
components of the tumor stroma are initially recruited from the host tissue and 
reprogramed to take various tumor promoting roles as the tumor progresses [15]. In order 
to curb the growing tumor it is necessary to fight the environment that is contributing to 
its growth [3, 4, 9, 16]. These underlying signatures of the tumor microenvironment can 
be exploited for diagnosis and treatment of a tumor by developing novel targeted drugs 
and drug delivery agents for tumor specific accumulation and action [17-22]. 
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Figure 1.1: The hallmarks of a tumor microenvironment. The non-malignant and 
malignant cells comprising the TME form a complex organ, which is regularly recruiting 
and transforming cells to acquire and maintain the hallmark characteristics for its survival 
and progression. Modified from reference [5] 
 
1.1.1 Tumor vasculature and hypoxia 
The vasculature in normal tissues is a well-organized network of arteries, veins 
and capillaries that are maintained by well-regulated expression of pro- and anti-
angiogenic factors. A functioning lymphatic system along with the efficient vasculature 
helps in draining the excess build-up of fluid and removal of waste metabolic products 
from the interstitium [23]. The highly proliferating tumor cells quickly outgrow their 
blood supply which leads to formation of regions with hypoxia (≤10-15 torr pO2) [4, 5, 8, 
10, 11, 24-31]. The lack of oxygen leads to hypoxia-induced expression of hypoxia 
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inducible factor-α (HIF1 α) which up-regulates pro-angiogenesis factors such as vascular 
endothelial growth factor-A (VEGF-A) and vascular endothelial growth factor receptor 2 
(VEGFR2) [32-35]. The poorly regulated expression of angiogenesis growth factors 
within the tumor microenvironment such as VEGF induces formation of neo-vasculature 
that is extremely inefficient in structure and function. The fundamental properties of a 
tumor vasculature are: 1) hyper permeability, 2) immature (lack of pericyte coverage), 3) 
chaotic organization, 4) deteriorating diffusion geometry, 5) lack of blood vessel 
hierarchy and 6) arteriovenous shunts (figure 1.2 A). The discontinuous diameter of the 
vessels along with abrupt blunt ends, abnormal budges and irregular shape results in 
inefficient delivery of the blood and nutrients to the tumors [36, 37]. Paired with a poor 
lymphatic system, this leads to fluid and waste build up in the vessels and tumors which 
leads to increase interstitial fluid pressure [38, 39]. The tumor vasculature is well 
organized and mature at the tumor-host interface and deteriorates as we move towards the 
center of the tumors. As the tumor grows, the vascular density decreases and leads to 
formation of regions with necrosis.  
Depending on the characteristics of tumor vasculature, hypoxia can be subdivided 
into chronic (diffusion limited) and acute (perfusion limited) (figure 1.2 B). The capacity 
of oxygen to diffuse is limited to 100-150 µm [40] from the nearest blood vessels due to 
consumption: regions that are farther than this diffusion limit develop chronic hypoxia. 
The transient changes in blood flow due to tumultuous, collapsed and dilated blood 
vessels and abrupt blunt ends leads to development of transient, acute hypoxia in the 
tumors.  
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Figure 1.2: Representation of vasculature in normal tissues and tumors. (A) The 
vasculature in normal tissues is well organized with balanced hierarchy and a functional 
lymphatic system. In tumors the vasculature is tumultuous, lacking vascular hierarchy, 
underdeveloped with improper lining of the pericytes and smooth muscle cells leading to 
leaky vessels. The inefficient blood vessels are not capable of meeting the increased 
requirement of oxygen and nutrients by the tumor cells which leads to formation of 
hypoxia. (B) The combination of poor vasculature network and highly proliferating cells 
leads to formation of chronic or diffusion limited hypoxia as the oxygen is not able to 
diffuse further than 100-150 µm in distance. Conversely, presence of abrupt blunt ends, 
arteriovenous shunts, blockages and temporary collapse of vessels causes acute or 
perfusion limited hypoxia. Reproduced from [22] and [21]. 
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1.1.2 Significance of hypoxia 
Several studies have highlighted the direct or indirect contribution of hypoxia 
towards the acquisition and regulation of hallmark properties of tumors. Hypoxia is one 
of the most prominent features of a tumor’s microenvironment, that varies between 
different tumor types and plays an important and complex role in the regulation of many 
hallmark characteristics of a tumor, thus making its evaluation crucial for understanding a 
tumor’s characteristics and for the development of a personalized treatment protocol [10, 
41-47]. Hypoxia is known to promote angiogenesis, invasion and metastasis and its 
presence is considered a marker for poor clinical prognosis [5, 11, 28, 41-46, 48-50]. 
Hypoxia also promotes resistance to apoptosis, chemotherapy and radiation thus limiting 
the number of potentially useful therapeutic options.  The persistence of hypoxia leads to 
selection of genetic variants that are able to adapt and grow in the stressful environment 
and develop resistance to therapy. Hypoxia provides a powerful physiological stimulus 
that can be exploited as a tumor-specific condition, allowing for the rational design of 
hypoxia targeted therapies as well as hypoxia imaging techniques [18, 48, 51-57]. Recent 
studies have shown that cancer stem cells,(neoplastic cells or tumor initiating cells) that 
may play a role in various tumor promoting factors such as metastasis, invasion and 
resistance to therapy [58-64], are more likely to be present in hypoxic regions and that 
hypoxia aids in their regulation and maintenance [65-68]. The extent and severity of 
hypoxia can be spatially heterogeneous in tumors and fluctuate over time as the disease 
progresses [69-72]. Figure 1.3 depicts the cycle of events mediated by hypoxia that 
makes it a prevalent condition for tumors. 
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Figure 1.3: The schematic presentation of hypoxia mediated cycles in a tumor. As the 
tumor out-grows its initial vasculature, regions with hypoxia develop. Hypoxia in turns 
regulates the expression of pro-angiogenesis factors that lead to formation of 
neovasculature which is chaotic in nature. The consequence of chaotic and 
underdeveloped vasculature is an increase in regions of hypoxia, thus the vicious cycle 
continues. The chronic development of hypoxia leads to increase in mutations and clonal 
selection of variants with decreased apoptotic potential and increased angiogenic 
potential thus resulting in tumor propagation and resistance to therapy. Image modified 
from [73]. 
 
 
The outstripping of nutrients and oxygen supply in neoplasms due to the inability 
of vasculature to meet the increased demand by proliferating cells leads to formation of 
hypoxia, which results in induction of angiogenesis. The unchecked expression of 
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angiogenesis factors lead to development of chaotic vasculature which in turn increases 
the presence of hypoxia and thus the cycle continue (figure 1.3).  
The various contributions of hypoxia can be summarized as follows: 
1. Resistance to radiotherapy due to lack of the reactive oxygen species, 
2. Hypoxic stress slows the proliferation of cancer cells leading to development 
of resistance against chemotherapeutic drugs that target highly proliferating 
cells. The associated lack of blood vessel supply to the hypoxic regions also 
makes it difficult for the drugs to penetrate into these regions.  
3. Hypoxia induces increase in genomic instability (high mutation frequency) 
and heterogeneity, 
4. Due to the increased stress in the hypoxic microenvironment, the cells that 
survive are usually clonal variants with anti-apoptotic mutations and increased 
aggressiveness, 
5. Hypoxia also contributes towards increased tumor survival by evading the 
immune response, 
6. Hypoxia is known to upregulate factors that promote angiogenesis, tumor 
invasiveness, malignancy and metastasis. 
 
1.1.3 Hypoxia activated bioreductive pro-drugs 
Targeted cancer therapeutics has garnered increased interest in the last few 
decades as a means to selectively target the tumor regions with increased toxicity. The 
plethora of tumor promoting factors induced by hypoxia indicates that selective targeting 
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of hypoxic regions in the tumors has the potential to improve the therapeutic efficacy. 
Hypoxia was recognized as a high-priority target for the development of cancer selective 
therapeutics and was first demonstrated by hypoxia selective toxicity of nitroimidazoles 
[74]. Hypoxia targeted therapeutics are mainly classified into hypoxia activated bio-
reductive pro-drugs or HAPs and drugs for molecular targeting of hypoxia specific 
pathways such as HIF pathways [54]. The focus of this dissertation will be the 
application of HAPs and their dependence and effect on the tumor hypoxia. Hypoxia 
activated bioreductive pro-drugs are a category of hypoxia targeted therapies that 
selectively target the hypoxic regions by getting reduced into their toxic counterparts 
known as ‘effectors’ in the presence of hypoxia and exert toxicity via various 
mechanisms. 
An ideal HAP should have the following fundamental properties : 1) ability to 
reach the hypoxic regions of the tumor that are contributing towards tumor resistance and 
are particularly present towards the center of the tumor, 2) a higher hypoxic threshold for 
conversion into the toxic counterpart, 3) ability to impart toxicity to the hypoxic cells 
especially the non-proliferating population within the hypoxic fraction and 4) ability to 
exert a bystander effect towards the less hypoxic and proliferating tumor population. 
Other important characteristics include high stability and solubility of the drug. Apart 
from these intrinsic properties of the HAPs, the extrinsic properties are more tumor type 
dependent, such as the presence of reductases that would convert the pro-drug to its toxic 
counterpart and sensitivity of the tumor cells towards the toxic metabolite. These 
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properties determine the efficacy of HAP in a tumor model and thus should be considered 
while developing a novel HAP. 
A typical HAP is composed of three components: a trigger, linker and an effector 
[75]. The trigger determines the hypoxic selectivity and the hypoxic threshold for the pro-
drug conversion and the linker makes sure the drugs stays deactivated in a normoxic 
environment. The effector imparts toxicity to the hypoxic cells and then exerts its toxicity 
to surrounding cells via bystander effect. The clinical relevance of hypoxia has led to the 
development of several HAPs, for example, PR-104 [76], AQ4N [77], EO9 [78], TH-302 
[79], TH-4000 [80, 81] and tirapazamine [82]. A few of these HAPs are discussed in 
detail below. 
The efficacy of two HAPs, tirapazamine and PR509, were evaluated in this study.  
Tirapzamine, (3-amino-1,2,4-benzotriazine 1,4-N-oxide, TPZ [83-88], figure 1.4) is a 
prototypical HAP that was developed in mid-1980s. The agent shows selective 
cytotoxicity to hypoxic cells and causes DNA single and double strand breaks. TPZ gets 
activated (under mild hypoxia) by the one-electron reduction activation by cytochrome 
P450 reductase to form an intermediate radical.  In the absence of oxygen, the radical 
gets converted to hydroxyl or benzotriazinyl radicals that cause DNA double of single 
strand breaks.  In the presence of oxygen, the intermediate gets re-oxidized to form the 
parent compound. TPZ can also undergo 2-electron reduction pathway via NQO1 to form 
mono-N-oxide with very low toxicity (figure 1.4). TPZ showed promising results in the 
preclinical studies [89] and phase I and II trials in combination with cisplatin, etoposide 
and radiotherapy, but failed in phase III studies [90].  
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Figure 1.4: The mechanism of action of tirapazamine. TPZ gets activated (mild hypoxia) 
by the one-electron reduction activation by cytochrome P450 reductase to form an 
intermediate radical.  In the absence of oxygen, the radical gets converted to hydroxyl or 
benzotriazinyl radicals that cause DNA double of single strand breaks.  In the presence of 
oxygen, the intermediate gets back oxidized to form the parent compound. TPZ can also 
undergo 2-electron reduction pathway via NQO1 to form mono-N-oxide with very low 
toxicity Reproduced from [54] (http://creativecommons.org/licenses/by/4.0/). 
 
PR509 is a novel hypoxia-activated bioreductive pro-drug that gets converted to 
its toxic counterpart PR509E in hypoxic regions [91]. It is an irreversible multikinase 
inhibitor that targets the EGFR family of kinases and was developed by a group of 
scientists at the University of Auckland led by Dr. Adam Patterson. Currently, an analog 
of PR509 called TH4000 [80, 81] (Hypoxin
TM
, Threshold Pharmaceuticals, San 
Francisco, USA) is currently undergoing phase II clinical trial in advanced NSCLC and 
metastatic squamous cell carcinoma of the head and neck. The mechanism of action of 
PR509 is similar to that of TH4000 (figure 1.5). Briefly, TH4000 undergoes 1 electron 
reduction in regions with hypoxia and gets converted to a nitro radical anion that 
undergoes further fragmentation to form the toxic product. The pre-clinical studies with 
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PR-610 have shown its activity against NSCLC with wild-type and mutant EGFR [54, 
80, 81]. 
 
Figure 1.5:  Structure and mechanism of action of TH-4000. TH-4000 gets converted to a 
nitro radical anion via one electron reductases in the presence of hypoxia. The nitro-
radical anion undergoes further fragmentation to form the effector TH4000E that causes 
inhibition of the EGFR family of kinases. PR509 is an analog of TH4000 with chlorine 
replaced with fluorine. Reproduced from [54] 
(http://creativecommons.org/licenses/by/4.0/). 
 
Figure 1.6 Structure of the hypoxia activated pro-drugs discussed in this chapter. 
Reproduced from [54] (http://creativecommons.org/licenses/by/4.0/). 
 
The HAPs can also be broadly classified on the basis of their mechanism to 
impart toxicity to the hypoxic regions. Typically the toxic counterpart of the HAP either 
causes DNA damage via introducing breaks in DNA or inhibition of cell proliferation via 
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kinase inhibiting pathways. The DNA damaging agents have a cytotoxic effect resulting 
in the death of cancer cells while kinase inhibiting agents induce antiproliferative effects 
resulting in cytostasis [92]. The goal of our study was to investigate the effect of TPZ and 
PR509 (changes in tumor volume as well as oxygenation) in pre-clinical tumor models as 
the drugs represent both the class of HAPs respectively. We also studied the effect of 
PR509E in order to evaluate the role of molecular targets (EGFR in the case of PR509) in 
determining the effect of the toxic effectors as their efficacy is independent of the 
presence of hypoxia.  
EO9 (apaziquone [78, 93]) is an indolequinone derivative of mitomycin C that 
causes generation of DNA damaging species (figure 1.6 A). The drug showed selective 
toxicity to hypoxic cells that are devoid of NAD(P)H:quinone oxidoreductase 1 (NQO1, 
a cytosolic flavoprotein), but is also showed toxicity to aerobic cells that express high 
levels of NQO1. EO9 showed poor penetration and fast degradation and thus failed to 
show good results in the clinical trials with NSCLC, pancreatic, breast, colorectal and 
gastric cancers.  
TH-302 (evofsoamide [79, 94] (figure 1.6) is a recently developed 2-
nitroimidazole containing HAP that showed great potential in the pre-clinical [95, 96] as 
well as clinical trials, but failed in the phase III trials in pancreatic adenocarcinoma and 
soft tissue sarcoma and was discontinued in phase II trials of NSCLC [55]. The TH-302 
effector causes DNA cross-linking and cell cycle arrest [97].  
PR-104 [76] is a nitroaromatic compund that causes DNA cross-linking in 
hypoxic cells via reduction by cytochrome P450 reductase (figure 1.6 C). The agent also 
13 
 
shows toxicity to aerobic cells  due to the oxygen-independent reduction by AKR1C3 
(aldo–ketoreductase 1C3). The PR-104 performed well in the pre-clinical [98] studies and 
phase I/II clinical trials[99] but unfortunately failed to show survival benefit and were 
discontinued [55].  
1.2 Magnetic Resonance Imaging 
MRI is a non-invasive tomographic imaging technique based on the phenomenon 
of nuclear magnetic resonance (NMR). MRI utilizes the fundamental property of nuclear 
spin to detect measurable signals arising from bulk nuclear spin polarization in presence 
of an external magnetic field (nuclear paramagnetism). Two- and three-dimensional 
images of the body with high spatial resolution and contrast can be generated using MRI 
by acquiring these signals in the presence of position encoding gradients [100]. Advances 
in the last three decades have led to a substantial improvement in the quality of the MR 
images generated with higher signal to noise ratio and sensitivity.  
Signal in MRI is generated from the electromagnetic radiations emitted when a 
nuclear spin is exposed to static and oscillating magnetic fields. Hydrogen atom contains 
a single proton with +1/2 and -1/2 nuclear spin states which results in a bulk magnetic 
moment in presence of a strong external magnetic field. This forms the basis for proton 
MRI that is widely prevalent in clinical settings. The human body is ~70% water by body 
weight and (along with hydrogen from fat) provides plenty of hydrogen protons that can 
be used as NMR active nuclei. Image contrast is defined as the ability to discriminate 
tissues based on their relative brightness and darkness on an image. Contrast obtained in 
the MRI images depends on several intrinsic properties of the tissue such as proton 
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density (ρ), diffusion, perfusion, spin-lattice relaxation time (T1), spin-spin relaxation 
time (T2), observed spin de-phasing time (T2*), magnetization transfer and chemical 
exchange effects. The images are generated by using specific “weighting” (e.g. T1 or T2 
weighting). Based on the choice of scanner settings, that exploits the differences in the 
above mentioned properties between the pathology and healthy tissue and results in 
image contrast that reflects the variation in the chosen property. For example the T1 and 
T2 of water at 1.5 T are ~ 4000 ms and 2000 ms, respectively [101]. Cerebrospinal fluid 
has similar T1 and T2 as water because the hydrogen protons are less restricted while fat 
protons have restricted mobility, resulting in shorter T1 (280-340 ms) and T2 (60-100 ms). 
In comparison, the T1 and T2 of white matter are ~ 800 ms and 80 ms, respectively, while 
those for gray matter are slightly longer with values ~1100 ms and 90 ms, respectively. 
Abnormalities such as edema, tumor, inflammation, infarction and infection have 
increased water content (in the case of tumors, lower cell density as well) and can be 
detected by using T2 weighting during the MRI acquisition as they appear bright 
compared to their surrounding normal tissue. In a routine clinical examination, T2 
weighted scan is often the first indicator of presence of an abnormality. A T1-weighted 
scan is often used at lower clinical magnetic field such as 1 or 1.5 T. 
The first images of a tumor were generated in 1971 and paved the path for use of 
MR for discrimination of tumors from surrounding tissues based on differences in 
relaxation times [102]. MRI provides an excellent platform for non-invasive in-vivo 
molecular imaging of cancer, providing superior soft tissue contrast and high resolution 
with moderate sensitivity compared to other imaging modalities [103]. MRI can generate 
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images depicting anatomical, biochemical and functional information while offering a 
good balance between image resolution and imaging time [104]. Additionally, MRI can 
also help in identifying the hallmarks of cancer and lead to development, analysis and 
therapeutic response assessment of improved targeted therapies on tumors.  
 
1.2.2 Paramagnetic relaxation enhancement 
MRI contrast agents are biocompatible, small-molecular or nanoscale chemical 
entities introduced exogenously into the body to improve the contrast between the area of 
interest and the surrounding tissue. The properties and advantages of contrast agents were 
first outlined by Lauffer in 1987 [105] and since then tremendous improvements have 
been achieved in the field of contrast agents and several new agents are developed each 
year [103, 106-111]. MRI based contrast agents typically use paramagnetic molecules 
(e.g. chelates of gadolinium or iron oxide) to enhance the contrast of the region of their 
accumulation by shortening the relaxation times of the water protons around them [105]. 
The majority of gadolinium based contrast agents are T1 relaxation agents and improve 
the contrast of the region of accumulation in a T1 weighted image. On the other hand, 
iron oxide based contrast agents are predominantly T2 weighted agents and make the 
accumulation region appear dark on a T2 or T2* weighted image. The efficiency of a 
contrast agent is based on its relaxivity (r1 or r2), which is the change in spin-lattice 
relaxation rate R1 (= 1/T1) or spin-spin relaxation rate R2 (=1/T2), respectively, of water 
per unit concentration of contrast agent. The relaxivity is typically calculated by 
measuring the relaxation rate (R1 or R2) as a function of agent concentration and by 
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determining the slope of the graph (R1 or R2 vs. concentration). The relationship between 
the relaxation times, the relaxivity and the concentration of the contrast agent is given by 
the following equation: 
         1/Ti (measured) = 1/Ti (water) + ri [Agent]; i= 1 or 2                                         [1.1] 
Here i= 1 or 2 and refers to the T1 and T2 relaxation times, respectively. The important 
properties that influence contrast agent relaxivity are (a) spin S and the electronic 
relaxation times Tie of the paramagnetic ion (b) the number of inner (directly coordinated 
to the Ln atom) and outer (hydrogen-bonded) coordination sphere water molecules (q and 
q’ respectively), (c) the residence lifetime of the inner and outer sphere water molecule(s) 
(m and m’ respectively), (d) the tumbling time of the agent in solution (R, rotational 
correlation time), (e) the distance between water proton and metaland (f) magnetic field 
strength (figure 1.7).  
The major contribution to the relaxation properties of the contrast agents is due to the 
inner sphere mechanisms. This contribution is given by: 
mm
mIS
i
T
qP
r


1
;    i= 1                                                             [1.2]  
Where; Pm = the mole fraction of metal ion; 
              q = number of bound water molecules per metal ion; 
              T1m = relaxation time of the bound water protons; and  
              m = residence lifetime of the bound water.  
Magnetic field strength alters the relaxation rate of the contrast agent which 
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typically decreases with increasing field strength (at slower tumbling time) [112]. The 
relaxation rate at clinically relevant field depends mainly on the m and R properties of 
the agent. Reduction in the rotational correlation time of the agent, which can be achieved 
by increasing the molecular weight of the agent, causes an increase in the relaxivity of the 
agent but the increases in r2 dominate over r1 at higher fields, as discussed by Caravan et 
al. in detail [113]. If the residence time of water protons in the inner sphere is long then 
the corresponding exchange of relaxed water with the bulk water is limited, thus resulting 
in lower relaxation rate. On the other hand, very short residence time also results in lower 
relaxation rates due to an inefficient relaxation of the bound water. Thus there is an 
optimum range of residence time for which the relaxation of the agent is highest. Many of 
these properties can be altered in order to develop improved contrast agents for cancer 
imaging by rational design of the chelate ligand [107]. 
Targeted exogenous contrast agents can alter the T1 (and T2 or T2*) of the tissues 
and result in increased contrast as compared to non-targeted contrast agents. The factors 
influencing the relaxivity of targeted contrast agents in described in figure 1.7.  
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Figure 1.7:  Factors influencing the solvent water relaxation and strategies for controlling 
rotational dynamics of multimeric, targeted contrast agents. IS: inner sphere, OS: outer 
sphere, T1e/T2e: electronic relaxation times, S: electron spin, τr: rotation tumbling time, 
τm: residence lifetime of water molecule, T1m /T2m: relaxation times of bound water, r: 
Ln-H distance for IS water molecules, q: number of IS water molecules, TA: targeting 
agent/ligand). Corresponding parameters for OS water molecules are denoted with a 
prime (‘) e.g r’: Ln-H distance for OS water molecules. 
(Note Section 1.2 is based on the paper -  Agarwal S and Kodibagkar VD. “Targeted 
Contrast Agents for 1H MRI of tumor microenvironment” Cancer Therapeutics and 
Imaging: Molecular and Cellular Engineering and Nanobiomedicine World Scientific 
Publishing. Eds, Rege K and Goklany S. 2016 (In press, accepted 4/9/16)) 
 
1.3 Assessment of tissue oxygenation 
As discussed before in detail, the assessment of tumor oxygenation is crucial and 
an effective oximetry technique that can facilitate the identification of hypoxic regions 
within the tumor can drastically improve our understanding of the tumor behavior and 
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eventually result in better cancer therapeutics. In this section, I will be discussing the 
various established and novel oximetry techniques for qualitative and quantitative 
assessment of tissue oxygenation. In particular, I will discuss in detail the two novel 
oximetry techniques that I used for the assessment of hypoxia in my research.  
1.3.1 Existing methods for measurement of pO2 
Assessment of oxygenation status can be achieved by various invasive and non-
invasive techniques [114, 115]. In-vivo invasive techniques such as polarographic needle 
electrodes[116] and fiber optic probe[117] techniques can measure the local pO2 and can 
facilitate multiple measurements throughout the tumor to get an estimate of the 
oxygenation distribution throughout the tumor. Ex-vivo immunohistochemical hypoxic 
markers (EF5 [118], HIF1α [119], pimonidazole, CAIX) [120, 121] enable visualization 
of hypoxia or related molecular events throughout the tumor at higher resolution and can 
also be used to analyze necrosis, perfusion and expression of hypoxia regulated proteins 
when paired with other IHC agents. The technique provides qualitative information of 
hypoxia and given the dynamic nature of hypoxia might not reflect the status of the tumor 
by the time treatment is administered, if the ex-vivo analysis is performed with tissue 
samples obtained well before the start of treatment.  
Non-invasive oximetry techniques include imaging agents for NIR spectroscopy 
[122], phosphorescence quenching [123],  positron emission tomography (PET) [124], 
single photon emission computed tomography (SPECT) [106, 125]  and MR based 
imaging techniques [114]. NIR spectroscopy is a non-invasive, portable technique that 
detects the changes in vascular oxygen saturation with high temporal resolution and can 
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facilitate measurements from limited depth in the tissue [126]. PET imaging agents 
[
18
F]fluoromisonidazole (
18
F-MISO), [
18
F]fluoroazomycin arabinoside (FAZA), [
18
F]-
EF5, [
18
F] fluoroerythronitroimidazole (FETNIM) and [
64
Cu]-diacetyl-bis(N(4)-
methylthiosemicarbazone (Cu-ATSM) and [
19
F] Tri-Fluoromisonidazole (TF-MISO) 
contain the 2-nitroimidazole moiety and have been evaluated as hypoxia binding agents 
[127]. Nitroimidazoles were discovered to be radiosensitizers for hypoxic cells in 1974 
[128] and since then significant research has been carried out on their ability to sensitize 
cancer cells [129-131]. The PET or SPECT agents show selective binding to the hypoxic 
regions and facilitate the differentiation between hypoxic and normoxic regions of a 
tumor. Agents such as 
18
F-AZA and 
18
F-MISO have shown the ability to determine the 
hypoxic fraction [132] of tumors and predict the treatment outcome in clinical studies 
[133, 134] respectively. However PET and SPECT based techniques lack spatial 
resolution, cannot provide quantitative oximetry information, are not suitable for repeated 
measurements.  
The current MR based oximetry techniques can be sub-divided into qualitative 
techniques Blood Oxygen Level Dependent (BOLD) [135], Tissue Oxygen Level 
Dependent (TOLD) [136], oxygen-enhanced MRI [137] and quantitative techniques EPR 
[138], 
19
F NMR of perfluorocarbon emulsions, e.g. FREDOM (utilizing 
19
F MRI of 
hexafluorobenzene, a reporter for oxygen [139]) and its 
1
H MR analog HMDSO based 
imaging called PISTOL [140, 141]. BOLD-MRI signal is dependent on the paramagnetic 
deoxyhemoglobin (R2*) and can facilitate oxygenation imaging at high spatial and 
temporal resolution. Previous studies have shown that BOLD signal changes are 
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correlated with the changes in pO2 [135, 142]. TOLD and OE-MRI signals are also 
qualitative oximetry imaging methods and dependent on the paramagnetic molecular 
oxygen’s influence on the water spin-lattice relaxation rate (R1). OE-MRI has shown 
great potential for measuring the hypoxic fraction of tumors and can be used to study 
cyclic hypoxia (as it facilitates repeated measurements) and the effect of carbogen 
breathing [143].  
The EPR oximetry technique is a minimally invasive technique that can provide 
quantitative oxygenation information via measuring the change in linewidth of an 
exogenously administered paramagnetic spin probe as it interacts with molecular oxygen.  
The technique can be used to obtain multiple measurements of the same region in tumors. 
Some of the EPR probes are LiPc, LiNc, Fusinite, Gloxy, India Ink, TAM etc, of which 
only India Ink is approved for clinical use [138, 144]. The 
19
F NMR oximetry uses 
exogenous perfluorocarbon reporters such as perfluoro-15-crown-5-ether (15C5 [145]) as 
oxygen reporters. FREDOM (Fluorocarbon Relaxometry using Echo planar imaging for 
Dynamic Oxygen Mapping) is a technique that exploits the linear relationship of the 
relaxation rate of hexafluorobenzene (HFB) with oxygenation and has the potential to 
provide quantitative measurements of the tissue oxygenation sequentially and can be used 
to monitor the response of tumors to hyperoxic gas.    
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1.3.2 Quantitative MR oximetry using PISTOL 
PISTOL (Proton Imaging of Siloxanes to Map Tissue Oxygenation Levels) is a 
quantitative 
1
H MR oximetry technique that was developed by Kodibagkar et al. [140, 
141]. PISTOL exploits the linear relationship of relaxation rate (R1) of oxygen reporter 
probe (siloxanes) with pO2.  
The molecular oxygen is paramagnetic in nature and shortens the longitudinal 
relaxation time. The oxygen reporter molecules should possess high hydrophobicity to 
ensure exchange of gases between the reporter molecule and environment, and a high 
solubility for oxygen. Various linear siloxanes such as hexamethyldisiloxane (HMDSO, 
figure 1.8 A), octamethyltrisiloxane (OMTSO), decamethyltetrasiloxane (DMTSO), 
dodecamethylpentasiloxane (DDMPSO), polydimethylsiloxane (PDMSO, trimethylsiloxy 
terminated, M.W. 410) and cyclic siloxanes octamethylcyclotetrasiloxane (OMCTSO) 
and decamethylcyclopentasiloxane (DMCPSO) as well as perfluorocarbons have the 
characteristics to be utilized as oxygen reporter molecules. PISTOL has been established 
as a quantitative oximetry technique that allows for accurate, non-invasive and repeated 
measurement of tissue oxygenation using HMDSO and HMDSO based nanoemulsions at 
4.7 T [140, 141, 146]. The calibration of HMDSO at 4.7 T showed the reporter’s 
sensitivity to changes in pO2 while less prone to changes in temperature (figure 1.8 B). 
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Figure 1.8: A) Chemical structure of hexamethyldisiloxane (HMDSO). B) Calibration of 
neat HMDSO at 0%, 5%, 10%, and 21% Oxygen Concentrations at 37ºC. Fitting data to 
the linear model R1= A’+B’* pO2 resulted in calibration constants A’ = 0.11056 ± 
6.54x10
-4
 and B’ = 0.00108 ± 1.7x10-5.  
 
The pulse sequence for PISTOL consists of the following components: 1) 20 non-
selective saturation pulses, followed by a tau delay for magnetization recovery, 2) 3 
CHESS pulses for selective saturation of water and fat, 3) An EPI based spin-echo 
acquisition with frequency selective π/2 pulse (on-resonance for siloxane), followed by a 
4) slice selective π pulse, and an EPI readout (figure 1.9).  
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Figure 1.9: Schematic representation of the pulse sequence for PISTOL. Modified from 
reference [141]. 
 
The relationship between the relaxation rate of reporter molecule and pO2 can be 
obtained by considering two pools of protons: a diamagnetic component that is due to the 
longitudinal relaxation rate of protons without oxygen in its neighborhood (R1d) and a 
combined paramagnetic (R1p) and diamagnetic component due to the proton in the 
vicinity of oxygen (R1d + R1p). The relaxation rate for both the pools of protons can be 
represented as a molar weighted average, where x is the molar fraction of the oxygen:  
                           R1 = (1 − x) ∗ R1d + x ∗ (R1d + R1p) =  R1d + x ∗ R1p [1.3] 
According to Henry’s law, the partial pressure of oxygen is directly related to the mole 
fraction of dissolved oxygen.  
                                                              pO2 = k ∗ x                                                      [1.4] 
where k is the solubility coefficient of oxygen. Thus, equation 1.3 can be 
rewritten as: 
                                                          R1 = A' + B' ∗ pO2                                               [1.5] 
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Where, A’ is the diamagnetic i.e. anoxic component (R1d) and B’ is the 
paramagnetic component that is dependent on pO2 (R1p/k).  
The temperature dependence of the A’ and B’ components can be approximated 
as: 
A' =  A + C ∗ T  
                                                           B' =  B + D ∗ T                                                  [1.6] 
Thus, a temperature dependent model for estimation of pO2 can be obtained by 
substituting the values from equation 1.8 in equation 1.7. 
                                         R1 = A + B ∗ pO2 + C ∗ T + D ∗ T ∗ pO2                            [1.7] 
The above equation can be used to determine oxygenation levels as well as errors 
in estimation pO2/°C, thus providing a more accurate and reliable quantification. The 
following equation can be used to determine error in pO2 determination for change in 
temperature by 1°C at a particular temperature T and oxygenation level: 
 
∆pO2
∆T
=
|C + D∗pO2|
B + D∗T
         [1.8] 
 
1.3.3 Qualitative MR oximetry using GdDO3NI 
An important alternate strategy for imaging hypoxia exploits the principle of 
selective enzyme mediated reduction of the nitro group in 2-nitroimidazole containing 
compounds under hypoxic conditions. Rojas-Quijano, et al., in 2012 reported a novel 
hypoxia-targeted contrast agent GdDO3NI [147]. The agent was prepared by conjugation 
of DO3A-monamide with 2-nitroimidazole moiety, which has been used to sensitize the 
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hypoxic tumors to radiotherapies [148]. The hypoxia selective enzyme mediated 
reduction of nitro group leads to accumulation and binding of the contrast agent in the 
hypoxic regions [149, 150]. The agent (figure 1.10) has r1 relaxivity of 5.21 ± 0.04 
mM
−1
s
−1
 and r2 relaxivity of 4.74 ± 0.03 mM
−1
s
−1
 in PBS at 4.7 T. The in-vivo hypoxia 
imaging of rat prostate adenocarcinoma AT1 tumors with GdDO3NI reported the utility 
of the agent in distinguishing between the normoxic and hypoxic regions within the 
tumor [151]. The agent has also shown ability in mapping the differential response of 
tumor hypoxia to hyperoxic gas breathing in prostate cancer sublines [152]. The agent 
has the potential to generate three-dimensional distribution maps of hypoxia, which can 
be utilized by clinicians for planning radiation and therapy. 
 
Figure 1.10: Structure of GdDO3NI. The 2-nitroimidazole moiety is highlighted in the 
blue circle.  
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CHAPTER 2 
QUANTITATIVE ASSESSMENT OF CHANGES IN TUMOR OXYGENATION 
POST HYPOXIA ACTIVATED THERAPY USING PISTOL 
 
2.1 Abstract 
In the present study, a novel pO2 measuring technique PISTOL (Proton Imaging 
of Siloxanes to map Tissue Oxygenation Levels) was used to determine the baseline 
oxygenation of pre-clinical xenograft tumor models of NSCLC (NCI-H1975) and 
epidermoid carcinoma (A431) and their response to hypoxia-activated pro-drugs (HAPs) 
PR509, its effector PR509E and tirapazamine (TPZ). The A431 tumor model had lower 
baseline oxygenation than the NCI-H1975 tumor model (p<0.05). PR509 and PR509E 
were effective slowing the growth of NCI-H1975 (p<0.05) and A431 tumors (p<0.01) as 
compared to untreated control cohorts. PR509E and TPZ resulted in a significant increase 
in the oxygenation of A431 tumor centers (p<0.05). TPZ was effective in slowing the 
tumor growth only in NCI-H1975 tumors despite the fact that A431 tumors were more 
hypoxic (p<0.05). TPZ resulted in a significant decrease in the oxygenation of NCI-
H1975 tumor centers as a result of its anti-vascular effect (p<0.05). In conclusion, 
PISTOL was able to report the changes in tumor oxygenation in both the tumor 
xenografts. The results indicate that other factors such as tumor perfusion (essential for 
delivering TPZ) and relative expression of nitroreductases (essential for activating HAPs) 
may play an important role. 
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2.2 Introduction 
Hypoxia is a characteristic feature of many tumor types, for example, prostate 
[153, 154], cervical [154, 155], lung [29-31, 156-158], glioblastoma [159, 160], breast 
[154] and head and neck cancer [49, 154, 161]. The clinical relevance of hypoxia has led 
to the development of several hypoxia-targeting therapeutics (discussed in detail in 
section 1.1.3). The failure of several promising HAPs calls for an in-depth evaluation of 
tumor hypoxia, its heterogeneity and its contribution towards treatment resistance and 
progression to improve clinical decision-making [127, 162-166].  
PISTOL (Proton Imaging of Siloxanes for mapping Tissue Oxygenation Levels) 
([140, 141] is a recently developed oximetry technique, and as discussed earlier in section 
1.3.2, has the potential to provide direct quantitative measurement of oxygenation non-
invasively and longitudinally along with the spatial distribution and degree of hypoxia. 
Here I used PISTOL to quantitatively map the oxygenation of tumor xenograft models 
pre and post hypoxia-activated therapies (HAPs). I investigated the efficacy of a novel 
pro-drug PR509 and its effector PR509E and compared it with tirapazamine, a 
prototypical DNA damaging hypoxia-activated pro-drug, in non-small cell lung cancer 
(NCI-H1975) and epidermoid carcinoma (A431) xenograft models. The main purpose of 
this study was to 1) study the baseline oxygenation of tumor xenograft models, 2) 
investigate the relationship between tumor oxygenation and the efficacy of hypoxia-
activated pro-drugs, 3) demonstrate the potential of PISTOL for identifying, and 
categorizing tumors with hypoxia and 4) to test the hypothesis that identification of 
tumors with hypoxia could assist in predicting the treatment outcome. 
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2.3 Materials & Methods 
2.3.1 Animal models 
Human NCI-H1975 non-small cell lung cancer and A431 epidermoid carcinoma 
cells (ATCC Inc.) were cultured in Roswell Park Memorial Institute (RPMI 1640) media 
and Dulbecco’s Modified Eagle’s Medium (DMEM) respectively, supplemented with 1% 
penicillin/streptomycin and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, 
USA), in a 5% CO2-containing humidified atmosphere at 37
0
C. The tumor models were 
selected based on the studies conducted by our collaborators by our collaborators, Dr. 
Adam Patterson and Dr. Jeff Smaill from The University of Auckland, to test the novel 
hypoxia-activated pro-drug PR509 and its toxic counterpart PR509E. 
Immunocompromised nu\nu mice (5-11/per cohort, Charles River Laboratories, USA) 
were implanted subcutaneously with 2x10
6
/40 µl cells of the respective cell line (A431 or 
NCI-H1975) in the right thigh. The animals were monitored and maintained as per the 
guidelines by The Arizona State University Institutional Animal Care and Use 
Committee (IACUC). 
 
2.3.2 Hypoxia-targeted therapy 
The mice bearing NCI-H1975 and A431 tumors were treated with a multi-kinase 
inhibitor hypoxia-activated prodrug called PR509 (60 µmole/kg), its effector PR509E (60 
µmole/kg) and tirapazamine (TPZ, 60 µmole/kg, Sigma Aldrich). The respective 
therapies were administered immediately after the acquisition of baseline PISTOL maps.  
PR509 and TPZ were dissolved in 5% dextrose while PR509E was dissolved in an acidic 
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buffer at pH 4.5 and administered intraperitoneally. The vehicle 5% dextrose was 
administered as a control agent. PR509 and PR509E were generously provided by Dr. 
Adam Patterson from University of Auckland, New Zealand. 
 
2.3.3 Tumor Volume Measurements 
Tumor volume measurements were made using Vernier calipers every 3
rd
 day 
from the day of tumor appearance until tumor excision (day 20). The formula for an 
ellipsoid (πabc/6), where a, b and c are three longest orthogonal dimensions (with a being 
the longest), was used to calculate the tumor volumes. Tumor volumes were normalized 
to baseline imaging (pre-treatment) volumes and then compared with post-treatment 
volumes to study the treatment response. Tumor doubling times were measured by fitting 
the mean normalized tumor volumes to a standard exponential growth curve. 
 
2.3.4 MR imaging protocol 
The following imaging protocol was followed to assess the baseline oxygenation 
of NCI-H1975 and A431 tumor models: Baseline (day 0) PISTOL maps were acquired 
once the tumors reached ~300 mm
3
 in volume. Neat HMDSO (Sigma Aldrich., 10-50 μL) 
was injected directly into the tumor using a Hamilton syringe with 32 Gauge needle and 
HMDSO droplets were deposited in a fan pattern, as shown in reference [167], along a 
single plane (figure 2.1). The mice were then placed on a mouse bed a mouse brain 
receiver coil was placed over the tumor. The mouse bed was then pushed inside the 
magnet and imaged using a mouse surface receiver and a volume transmitter coil. The 
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body temperature of mice was maintained by keeping them on a heated water-bed at 
37
0
C. After positioning the mouse inside the scanner, a standard multi-slice multi-echo 
(MSME) T2 mapping sequence was used to calculate T2 (TR = 3 s & TE = 14-210 ms, 
total 15 TEs, matrix 128 x 128 and FOV 2 cm) of tumor followed by acquisition of three 
consecutive PISTOL T1 maps. The mice were kept under anesthesia (air and 1.5% 
isoflurane; Veterinary Anesthesia Systems Inc.) during the entire course of experiment. 
At the end of the imaging protocol, respective therapy (TPZ, PR509, PR509E or 5% 
dextrose) was injected intraperitoneally. Subsequent imaging was conducted every 5
th
 
day until day 15 post baseline imaging i.e. at day 5, 10 and 15.  
A custom built T1 mapping MATLAB code was used to compute mean pO2 from 
the PISTOL maps, as described previously [141]. The T1 values obtained were used to 
obtain the pO2 values via equation [1.5]. Based on the calibration of neat HMDSO at 
37ºC at 7 T (shown in section 1.3.2) the T1 threshold was set at <9.05 s (i.e. pO2 greater 
than 0 torr) and >3.5 s (i.e. pO2 less than 160 torr). Mean pO2 value from the three pO2 
maps generated from the respective three PISTOL maps was computed and compared for 
each tumor. In order to study the heterogeneity in tumor, we used a T2 weighted image 
from the acquired MSME T2 images to delineate the tumor and segmented it into 
periphery and central regions (outer and inner 50% voxels in order to equally segment the 
tumor into two regions, respectively, figure 2.4) and average pO2 for both the regions as 
well as the whole tumor were analyzed.  
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Figure 2.1: The representation of experiment set-up. Neat HMDSO droplets were 
deposited directly into the tumor using a Hamilton syringe in a fan pattern at axial plane. 
 
 
Figure 2.2: Schematic representation of the study protocol. 
 
Figure 2.3: Schematic representation of the imaging protocol. 
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Figure 2.4: Representation of the image segmentation procedure for data analysis. (a) 
tumor region with the ROI applied to delineate tumor from thigh region. (b) The 
generated tumor mask and the corresponding center (c) and periphery (d) masks.  
 
2.3.5 Tumor collection and immunohistochemical analysis 
Three different tumors from each cohort were examined. 60 minutes prior to 
euthanization, the mice were injected intraperitoneally with 60 mgs/kg/body weight 
pimonidazole HCL (Hypoxyprobe Inc.). The mice were then placed under anesthesia and 
then euthanized by cervical dislocation. The tumors were surgically removed and 
embedded in optimum cutting temperature compound (OCT) placed in a cryomold and 
frozen on dry ice and stored at -80 
º
C until further processing. For ex-vivo analysis of 
hypoxia, 25 µm thick tumor sections were obtained using a cryostat and placed on a 
microscope slide. The tumor section corresponding to the slice location of PISTOL maps 
were selected and stained with FITC conjugated anti-pimonidazole antibody (1:200) 
overnight at 4
0
C and counterstained with DAPI (300 nM, nucleic acid stain). The stained 
section were visualized under a fluorescence microscope (Leica Biosystems) using the 
GFP channel (EX: 450-490 nm, EM: 500-550 nm) for pimonidazole and the blue channel 
(EX: 355-425 nm, EM: 470 nm) for DAPI at 5X magnification. Hypoxic fractions were 
calculated using a custom made MATLAB code. Briefly, the image was split into blue 
(DAPI) and green (Pimo) channels. The blue channel image was used to delineate the 
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tumor and applied to the green channel image. A region of interest was then drawn within 
the green channel image corresponding to the tumor around a region with minimum 
intensity and its mean and standard deviation was calculated.  Regions with value 2 
standard deviations above the mean of were considered as hypoxic and used to calculate 
the hypoxic fraction. The hypoxic fractions of all the cohorts were then compared for 
analysis.  
 
2.3.6 Edema fraction analysis 
We investigated the occurrence of edema in the tumors pre and post treatment and 
analyzed the correlation with the treatment. The inefficient vasculature and lymphatic 
system in the tumors leads to formation of regions with higher fluid accumulation or 
edema. Edema can also result from the necrosis and treatment induced cell-death. Edema 
has higher T2 as compared to the tumors [168]. The edema fraction was calculated by 
applying a bi-exponential fit model, a modification of the model described here [169, 
170], to the acquired T2 maps using a custom made MATLAB code. Pixel by pixel 
computation of short (0-200 ms) and long T2 (>200 ms) components was conducted to 
calculate the edema fraction. Mean edema fraction (fraction of pixels with long T2 
component) was then calculated for the entire volume of the tumor.   
 
2.3.7 Data analysis 
Statistical analyses of all the tumor volume, oxygenation and edema fraction data 
were conducted via a Student T-Test using the GraphPad PRISM 7.0 Software 
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(GraphPad Inc., La Jolla CA). For statistical analysis alpha of <0.05 was considered as 
significant.  Un-paired T-Tests were conducted between the normalized tumor volumes 
for A431 and NCI-H1975 tumor bearing cohorts treated with PR509, PR509E, TPZ and 
untreated control to evaluate the treatment response. Un-paired T-Tests were also 
conducted to analyze the difference between the mean baseline oxygenation and mean 
edema fraction of the two tumor models. Paired t-tests were conducted to determine the 
baseline intra-tumoral variation in oxygenation of central and peripheral region. Paired T-
Tests were also conducted to determine the significance of changes between the 
oxygenation of tumors as well as edema fraction post treatment i.e. at day 5-15 from day 
0. Paired t-tests were also conducted between the oxygenation of central and peripheral 
region for each cohort. Un-paired T-Tests were conducted between the A431 and NCI-
H1975 tumor bearing mice treated with the same therapy. Tumor doubling times were 
calculated using the Origin 8.1 software (OriginLab Corporation).  
 
2.4 Results 
2.4.1 Baseline tumor oxygenation and edema fraction  
A total of 31 A431 and 32 NCI-H1975 tumor bearing animals were studied. In 
order to understand the baseline characteristics of A431 and NCI-H1975 tumors, the 
mean pO2 values derived from the PISTOL maps for each tumor type were compared 
using an unpaired t-test. The mean baseline (day 0) oxygenation of A431 tumors (32 ± 
12.5 torr) was found to be significantly lower than the NCI-H1975 tumors (47 ± 14 torr) 
(p<0.0001) (figure 2.5 A). Further comparison between the mean pO2 of tumor center and 
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periphery showed that A431 tumor centers had significantly lower oxygenation (27 ± 12 
torr) as compared to NCI-H1975 tumor centers (50 ± 17 torr , p<0.0001). The 
oxygenation of A431 tumor periphery (39 ± 15 torr) was also significantly lower than the 
NCI-H1975 tumors’ periphery (47 ± 15 torr, p<0.05). 
Figure 2.5: The baseline mean tumor oxygenation (A) and baseline edema fraction (B) of 
A431 (n = 31) and NCI-H1975 (n = 32) tumors. A431 tumors were significantly more 
hypoxic and had smaller edema fraction than NCI-H1975 tumors. Note: Black * 
represent statistical difference between A431 and NCI-H1975 tumors. Red * represent 
difference between the center and periphery of the respective tumor type (**** represents 
p<0.0001 and ** represents p<0.01).  
 
In order to determine the intra-tumoral variations we compared the mean 
oxygenation of the central and peripheral regions (figure 2.5 A). Paired t-tests showed 
that the A431 tumor centers had significantly lower oxygenation as compared to the 
periphery (p<0.005), while the center of NCI-H1975 tumors had slightly higher 
oxygenation than the tumor periphery but the difference was not statistically significant. 
Furthermore, we computed and compared the baseline mean edema fraction between the 
tumor models and found that A431 tumors (0.1 ± 0.02) had significantly lower edema 
fraction as compared to the NCI-H1975 tumors (0.16 ± 0.04, p<0.0001, figure 2.5 B). 
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2.4.2 Treatment response 
The efficacy of the HAP treatment was determined by analyzing the normalized 
mean tumor volume differences between the treated and untreated control cohorts. The 
mean normalized tumor volumes of PR509 and PR509E treated A431 tumors were 
significantly lower than the untreated control tumors (p<0.0001) at day 15 while TPZ 
treated A431 tumors were comparable to the control tumors (figure 2.6 A). The mean 
normalized tumor volumes of PR509 and PR509E treated NCI-H1975 tumors were 
significantly lower than the untreated control tumors (p<0.001 and p<0.05) at day 15 
(figure 2.6 B).  TPZ treated NCI-H1975 tumors were also significantly smaller as 
compared to the untreated control tumors at day 15 (p<0.05, figure 2.6 B). A significant 
difference was also observed between control A431 and NCI-H1975 normalized mean 
tumor volumes at day 15 with A431 control tumors being smaller than the NCI-H1975 
control tumors (p<0.05). PR509 was more effective than PR509E in NCI-H1975 
xenografts (p<0.06). 
We also investigated the tumor volume doubling times in order to evaluate the 
therapeutic effect and tumor prognosis. The mean volume doubling time for untreated 
A431 tumors was 7 ± 0.4 days while for NCI-H1975 tumors was 5 ± 0.4 days. PR509 and 
PR509E treated A431 tumors showed regression while those treated with TPZ had a 
doubling time of 7.5 ± 0.5 days. PR509, PR509E and TPZ treated NCI-H1975 tumors 
had a doubling time of 9 ± 0.8, 7 ± 0.2 and 7 ± 0.2 days respectively (Table 2.1). 
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Figure 2.6: The mean normalized tumor volumes of A431 and NCI-H1975 tumor treated 
with TPZ, PR509, PR509E and untreated control and their statistical differences. The 
PR509 and its effector PR509E treated A431 tumors had significantly lower mean 
normalized tumor volumes than the TPZ and untreated control tumors. While all the three 
treatments were successful in slowing down the tumor growth in NCI-H1975 cohorts and 
had significantly lower mean normalized tumor volumes than the untreated control.  
Note: The error bars represent the standard deviation. The statistical difference were 
calculated between the treated and untreated control normalized tumor volumes for both 
the tumor types (*** represents p<0.001 and * represents p<0.05). 
 
 
Table 2.1: Tumor doubling times of A431 and NCI-H1975 treated tumors. 
 Tumor doubling time (Days) 
 Untreated Control TPZ PR509 PR509E 
A431 7 ± 0.4 7.5 ± 0.5 N/A N/A 
NCI-H1975 5 ± 0.4 7 ± 0.2 9 ± 0.8 7 ± 0.2 
2.4.3 In-vivo Imaging 
We evaluated the therapy induced changes in the tumors’ oxygenation and 
compared them to baseline levels. We investigated the changes in the overall tumor 
oxygenation as well as in tumor center and periphery.  
2.4.3.1 In-vivo Imaging: Treatment response of epidermoid carcinoma A431 
Untreated Control: The untreated control A431 tumor centers had a significant 
increase in the oxygenation at day 15 (34 ± 10 torr) from the baseline levels (24 ± 12.5 
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torr, p<0.05). While, no significant change was observed in the periphery. The tumor did 
not show any significant intra-tumoral heterogeneity (center vs. periphery) in the 
oxygenation. The behavior of the untreated control cohort is shown in figure 2.7 (A).  
TPZ: The oxygenation of TPZ treated tumors increased post treatment and the 
difference was significant between day 15 (54 ± 11 torr, p<0.05) and baseline (30 ± 14 
torr) for the tumor centers. The behavior of the TPZ treated cohort is shown in figure 2.7 
(B). On the other hand, the changes in oxygenation of tumor periphery were not 
significant. We also observed that the tumor center (59 ± 11 torr) had significantly higher 
oxygenation than the tumor periphery (47 ± 13 torr, p<0.01) post-treatment at day 15.  
PR509: PR509 treated tumors initially showed a decrease in the mean 
oxygenation at day 10 (28 ± 7 torr) but a not significant increase was observed at day 15 
(38 ± 8 torr, p<0.08, fig 3C). The mean oxygenation at day 5 (28 ± 10 torr, p<0.08) of the 
tumor periphery was lower as compared to the baseline (41 ± 17 torr). The post-treatment 
(day 5) oxygenation of tumor centers was significantly lower as compared to the 
periphery. The behavior of the PR509 treated cohort is shown in figure 2.8 (A). 
PR509E: PR509E treatment of the A431 cohort resulted in a significant increase 
in the oxygenation of tumor centers at day 5 (41 ± 7 torr) and day 15 (52 ± 18 torr) from 
baseline (23 ± 8 torr, p<0.01). The peripheral regions’ oxygenation did not show any 
significant change for post-treatment. There were no significant intra-tumoral differences 
observed. The behavior of the PR509E treated cohort is shown in figure 2.8 (B). 
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Figure 2.7: The oxygenation changes of untreated control (n = 11) and TPZ treated  (n = 
7) A431 cohorts and their statistical comparison. Note: The error bars represent the 
standard deviation. The black colored * represents the significant difference from 
baseline and the red colored * represents the significant difference between the center and 
periphery (* represents p<0.05 and ** represents p<0.01). 
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Figure 2.8: The oxygenation changes of PR509 (n = 8) and PR509E (n = 5) treated A431 
cohorts and their statistical comparison. Note: The error bars represent the standard 
deviation. The black colored * represents the significant difference from baseline (* 
represents p<0.05). 
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Figure 2.9: Overlay of the reference T2-weighted tumor image and the respective pO2 
map from day 0 – 15 for all the four A431 cohorts. The region of interest (shown as red 
boundary) represents the segmentation that was conducted to delineate the tumor from 
surrounding tissue and also to segment the tumor into center and periphery. 
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2.4.3.2 In-vivo imaging: Treatment response of non-small cell lung cancer NCI-H1975 
Untreated control: Untreated control NCI-H1975 tumor centers as well as 
periphery had a significant decrease in the mean oxygenation of the tumor at day 5 from 
baseline (p<0.01). The tumor periphery had significantly lower oxygenation also at day 
10 (33.5 ± 9 torr) as compared to baseline (55 ± 19 torr). The behavior of the untreated 
control cohort is shown in figure 2.10 (A). 
TPZ: The TPZ treatment of NCI-H1975 tumors resulted in a decrease in the 
oxygenation at day 5 (40 ± 11 torr) and day 10 (40 ± 10 torr) of tumor centers from the 
baseline (55 ± 15 torr, p<0.05). The behavior of the TPZ treated cohort is shown in figure 
2.10 (B).  
PR509 & PR509E: The statistical analysis showed that PR509 treatment resulted 
in a significant decrease in the oxygenation of the tumor periphery at day 5 (24 ± 5 torr, 
p<0.05) from baseline (37 ± 11.5 torr, p<0.05). Post day 5, the oxygenation increased for 
both tumor center as well as periphery till day 15 and the increase was significant for 
tumor periphery at day 15.  In PR509E treated tumors, the oxygenation of tumor centers 
decreased significantly at day 15 (33 ± 18 torr) from baseline (47 ± 20 torr). The behavior 
of the PR509 and PR509E treated cohorts are shown in figure 2.11 (C & D).  
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Figure 2.10: The oxygenation changes of untreated control (n = 8) and TPZ treated (n = 
8) NCI-H1975 cohorts and their statistical comparison. Note: The error bars represent the 
standard deviation. The black colored * represents the significant difference from 
baseline. (* represents p<0.05 and ** represents p<0.01) 
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Figure 2.11: The oxygenation changes of PR509 (n = 8) and PR509E (n = 8) treated NCI-
H1975 cohorts and their statistical comparison. Note: The error bars represent the 
standard deviation. The black colored * represents the significant difference from 
baseline and the red colored * represents the significant difference from day 5. (* 
represents p<0.05) 
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Figure 2.12: Overlay of the reference T2-weighted tumor image and the respective pO2 
map from day 0 – 15 for all the four NCI-H1975 cohorts. The region of interest (shown 
as red boundary) represents the segmentation that was conducted to delineate the tumor 
from surrounding tissue and also to segment the tumor into center and periphery.  
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Table 2.2: Mean oxygenation of A431 and NCI-H1975 xenograft tumor models from day 
0 -15.  
  Mean pO2 (torr) 
Tumor 
Model 
Treatment  Day 0 Day 5 Day 10 Day 15 
A431  
Untreated 
Control 
(n = 8) 
Mean 28 ± 14 36 ±14 31 ± 14 38 ± 20 
Center 24 ± 11.5 41 ± 19 34 ± 15 34 ± 10 
Periphery 32 ± 13 32 ± 13 30 ± 13 36 ± 23 
 
TPZ 
(n = 8) 
Mean 36 ± 14 48 ± 12 46 ± 11 54 ± 11 
Center 30 ± 14 46 ± 10 49 ± 11 59 ± 11 
Periphery 46 ± 19 64 ± 29 42 ± 13 47 ± 13 
 
PR509 
(n = 8) 
Mean 32 ± 11 30 ± 10 28 ± 7 36 ± 8 
Center 30 ± 9 31 ± 10 29 ± 6 35 ± 13 
Periphery 41 ± 17 28 ±10 27 ±11 36 ± 8 
 
PR509E 
(n = 8) 
Mean 37.5 ± 8 41 ± 7 36 ± 10 53 ± 19 
Center 23 ± 8 41 ± 7 35 ± 9 52 ± 18 
Periphery 39.5 ± 8 38.5 ± 10 38 ± 16 55 ± 19 
NCI-H1975  
Untreated 
Control 
(n = 11) 
Mean 54 ± 16 35 ± 14 36± 13 42 ± 18 
Center 66 ± 14 36 ± 7 46 ± 31 49 ± 27 
Periphery 55 ± 19 37 ± 20 33.5 ± 9 35 ± 20 
 
TPZ 
(n = 7) 
Mean 48.5 ± 14 38 ± 12 39 ± 9 42 ± 9 
Center 55 ± 15 40 ± 11 40 ± 10 45 ± 13 
Periphery 45 ± 15 36 ± 14 36 ± 10 37 ± 8 
 
PR509 
(n = 8) 
Mean 38 ± 11 26 ± 6 30 ± 9 33.5 ± 8 
Center 38 ± 14 26 ± 8 31 ± 11 33 ± 11 
Periphery 37 ± 11.5 24 ± 5 29 ± 10 35 ± 9 
  
PR509E 
(n = 5) 
Mean 46.5 ± 11 39 ± 14 38 ± 19 30 ± 10 
Center 47 ± 20 40 ± 16 36 ± 18 29 ± 9 
Periphery 48 ± 9 39 ± 15 37 ± 19 33 ± 19 
 
2.4.4 Edema fraction 
Edema fractions were calculated from the analysis of T2 maps. We investigated 
the changes in edema fraction as a response to therapy and also compared the intra-
treatment differences in the mean edema fraction for each tumor model. Untreated 
control A431 tumors had a significant decrease in the edema fraction at day 10 (0.09 ± 
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0.02, p<0.05) and day 15 (0.08 ± 0.01, p<0.05) from the baseline (0.11 ± 0.03) (figure 
2.13). There were no significant changes observed in all the three treated A431 cohorts. 
Even a comparison among the edema fraction of treatments at same time point did not 
show any significant difference. Next, we compared the edema fractions of NCI-H1975 
tumors. The edema fraction of TPZ treated cohort was significantly lower than the 
untreated control cohort at all the time point post-treatment (figure 2.14). The edema 
fraction was even significantly lower than PR509E at day 10. The treatment with PR509 
resulted in a significantly lower edema fraction than untreated control at day 15. We also 
observed that the mean edema fraction of PR509 treated tumors were lower than the 
PR509E treated (p<0.06).  
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Figure 2.13: Treatment induced changes in edema fraction of A431 tumors. Note: The 
error bars represent the standard deviation. The black colored * represents the significant 
difference from baseline (* represents p<0.05).  
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Figure 2.14: Treatment induced changes in edema fraction of NCI-H1975 tumors. Note: 
The error bars represent the standard deviation. The black colored * represents the 
significant difference from untreated control cohort and the blue colored * represents the 
significant difference from at day 15 from day 10 of TPZ treated cohort (* represents 
p<0.05 and ** represents p<0.01). 
 
As stated above, the baseline edema fractions were significantly different for 
A431 and NCI-H1975 tumors. Next, we wanted to see the differences among the two 
tumor models treated with respective therapies. The statistical analysis of mean edema 
fraction changes between the respective A431 and NCI-H1975 cohorts showed that NCI-
H1975 tumors consistently had higher edema fraction post-treatment than their A431 
counterparts (figure 2.15). Table 2.3 lists all the mean edema fractions for all the 8 
cohorts.  
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Figure 2.15: Treatment induced changes in edema fraction A431 vs. NCI-H1975. Note: 
The error bars represent the standard deviation (* p<0.05, ** p<0.01, *** p<0.005 and 
**** p<0.0001). 
 
Table 2.3: Mean Edema fraction of A431 and NCI-H1975 xenograft tumor models.  
  Mean Edema Fraction 
Tumor Model Treatment Day 0 Day 5 Day 10 Day 15 
A431 Untreated control 0.11 ± 0.03 0.09 ± 0.03  0.09 ± 0.02 0.08 ± 0.01 
TPZ 0.09 ± 0.02 0.09 ± 0.02  0.09 ± 0.01 0.09 ± 0.02 
PR509 0.10 ± 0.01 0.08 ± 0.03  0.09 ± 0.03 0.08 ± 0.03 
PR509E 0.10 ± 0.02 0.11 ± 0.05  0.13 ± 0.06 0.09 ± 0.03 
NCI-H1975 Untreated control 0.17 ± 0.05 0.16 ± 0.02  0.18 ± 0.04 0.22 ± 0.05 
TPZ 0.14 ± 0.05 0.13 ± 0.02  0.12 ± 0.04 0.15 ± 0.05 
PR509 0.18 ± 0.04 0.14 ± 0.05  0.14 ± 0.03 0.14 ± 0.02 
PR509E 0.16 ± 0.01 0.14 ± 0.03  0.18 ± 0.04 0.19 ± 0.05 
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2.4.5 A431 vs. NCI-H1975 tumor oxygenation 
The heterogeneity of tumor behavior as a response to therapy is not well 
documented, thus we wanted to investigate the differences in behavior of our tumor 
models with respect to treatments. The comparison between the untreated control A431 
and NCI-H1975 tumors showed that the oxygenation between the cohorts was not 
significantly different (figure 2.16 A). The periphery of A431 tumors treated with TPZ 
had significantly higher mean oxygenation as compared to the NCI-H1975 tumors at day 
5 and day 15 (figure 2.16 B). The tumor centers of A431 cohort treated with PR509 had 
significantly lower oxygenation as compared to the NCI-H1975 cohort at day 10 (figure 
2.16 C). While periphery of A431 tumors treated with PR509E were significantly higher 
than the NCI-H1975 tumors at day 15 (figure 2.16 D).  
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Figure 2.16: A431 vs. NCI-H1975 oxygenation (* p<0.05). Note: The error bars 
represent the standard deviation. 
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In order to confirm the existence of hypoxia within the tumors post day 15 post-
therapy, we analyzed the distribution of hypoxia in tumors by immunohistochemical 
analysis of pimonidazole adducts based measurement of hypoxic fractions (gold standard 
for hypoxia). Three tumors from each cohort were selected for the ex-vivo analysis of 
hypoxia. The center of TPZ treated NCI-H1975 tumors (0.27 ± 0.10) had significantly 
higher hypoxic fraction than the PR509E treated tumors (0.08 ± 0.04, figure 2.17 C). 
PR509 treated NCI-H1975 tumor centers (0.10 ± 0.04) had lower hypoxic fraction than 
the tumor periphery (0.22 ± 0.04, figure 2.17 C). No significant difference was observed 
in the hypoxic fractions of rest of the cohorts. Table 4 contains all the mean hypoxic 
fractions from each cohort. 
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Figure 2.17: (A) The mean hypoxia fractions of A431 and NCI-H1975 cohorts, measured 
at day 15 post-treatment, by pimonidazole staining (n = 3). TPZ treatment of NCI-H1975 
tumors resulted in a higher extent of hypoxia as compared to other three NCI-H1975 
cohorts. The mean hypoxia fraction of (B) A431 and (C) NCI-H1975 tumors segmented 
into center and periphery. No significant changes were observed in the A431 tumors. In 
NCI-H1975 tumors, the TPZ treated tumor centers had significantly higher hypoxic 
fraction than the PR509E treated tumors and PR509 treated tumor centers had lower 
hypoxic fraction than the tumor periphery (* represents p<0.05). 
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Table 2.4: Mean hypoxic fraction of A431 and NCI-H1975 treated tumors computed 
from immunohistochemistry. 
 
 Mean Hypoxic Fraction 
 Untreated Control TPZ PR509 PR509E 
A431 0.21 ± 0.02 0.24 ± 0.08 0.3 ± 0.1 0.19 ± 0.08 
NCI-H1975 0.19 ± 0.03 0.4 ± 0.1 0.21 ± 0.06 0.18 ± 0.07 
 
 
Figure 2.18: Pimonidazole stained NCI-H1975 tumor sections treated with (a) untreated 
(b) TPZ (c) PR509 and (d) PR509E. The green color represents regions with 
Pimonidazole and the blue represents DAPI nuclear stain.  
 
 
 
 
56 
 
 
 
Figure 2.19: Pimonidazole stained A431 tumor sections treated with (a) untreated (b) 
TPZ (c) PR509 and (d) PR509E. The green color represents regions with Pimonidazole 
and the blue represents DAPI nuclear stain. 
 
2.5 Discussion 
Hypoxia, mostly chronic, modulates various cellular responses and signaling 
pathways that lead to selection of aggressive phenotype, malignant progression, invasion 
and metastasis [41-45]. Hypoxia targeted therapies have been in focus since the last 30 
years and are aimed at targeting the treatment limiting regions in the tumor 
microenvironment. The failure of various extensively studied HAPs calls for an in-depth 
57 
 
analysis of the design and functioning of HAPs as well as the contribution of hypoxia in 
their efficacy.  
Previous studies have shown that incorporation of hypoxia and perfusion imaging 
techniques (
18
F-FMISO PET and EPR oximtery) were able to predict the response to TH-
302 in squamous cell carcinoma SCCVII, human colon cancer cell line HT29, C6 
glioblastomas and 9L gliosarcomas [171, 172]. In this study, I investigated the efficacy of 
a novel HAP called PR509, its effector PR509E and tirapazamine in tumor xenograft 
models of non-small cell lung cancer (NCI-H1975) and epidermoid carcinoma (A431). 
The hypothesis was that information about the baseline oxygenation of tumor pre-therapy 
could be predictive and can throw light on other factors and complex processes that are 
involved in the effective working of these hypoxia-activated drugs in-vivo. The PISTOL 
technique was used in my study measure the tumor oxygenation before and after therapy.  
 A lower baseline oxygenation in A431 was observed as compared to NCI-H1975 
tumors. Previous PET based hypoxia imaging studies have shown the presence of 
hypoxia in A431 and NSCLC tumors [127, 173-175]. The distribution of hypoxia varies 
within the tumor regions and therefore the tumor was delineated into central and 
peripheral regions. A431 tumors had higher baseline intra-tumoral heterogeneity in the 
oxygenation of center and periphery, with center being more hypoxic. Both A431 and 
NCI-H1975 tumors responded to the PR509 and PR509E treatments. As expected, the 
more hypoxic A431 tumors had higher response than the NCI-H1975 tumors. The 
toxicity of PR509E is independent of the presence of hypoxia and thus highlights two 
important factors about the multi-kinase inhibitor HAPs: the presence of molecular 
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targets in the tumors and the toxicity level of the HAP. The efficacy of PR509 was higher 
as compared to PR509E in NCI-H1975 tumors as evidenced by the tumor doubling times. 
Previous clinical studies have shown that most NSCLC tumors acquired 
resistance against the first generation multi-kinase inhibitors such as geftinib and 
erlotinib [176]. The efficacy of EGFR-TKIs is dependent on the expression of wild-type 
EGFR and the types of mutations in EGFR (sensitizing or resistance inducing) and their 
level of expression. NCI-H1975 expresses the double-mutant L858R/T790M EGFR 
which imparts resistance against tyrosine kinase inhibitors [177], while A431 has 
overexpression of wild type EGFR [178]. EGFR receptors are over-expressed in regions 
with tumor hypoxia and are known to contribute towards increase tumor proliferation and 
resistance to therapy [179]. The efficacy of PR509E in A431 demonstrates that hypoxia 
was not the sole contributor towards the efficacy and that over-expression of EGFR 
kinases also contributed towards it. The efficacy of PR509E and PR509 in NCI-H1975 
tumors indicates the possibility that hypoxia was a contributor towards increased efficacy 
of PR509 than its effector. Studies conducted over TH4000, the analog of PR509 have 
shown that TH4000 was able to overcome the resistance to conventional tyrosine kinase 
inhibitors such as erlotinib in mutant EGFR NSCLC model [80]. Hypoxia is known as a 
driving factor for resistance to therapy, but it is not always the case in all the cancer sub-
types [55]. It is important that HAPs are able to target the hypoxic regions that are 
contributing towards resistance to conventional therapies. The effect of PR509 in NCI-
H1975 tumors shows that it was able to target the highly aggressive, tumor promoting 
regions of the tumors.  
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TPZ, on the other hand, showed a completely different efficacy between A431 
and NCI-H1975. Despite the fact that A431 tumors were more hypoxic, the TPZ 
treatment was only effective in NCI-H1975 tumors. The mild activation threshold of TPZ 
might affect its diffusion range, resulting in early metabolism of the drug before reaching 
the severe hypoxic regions of the A431 tumors [180]. Previous studies have shown that 
TPZ does not work well with highly dense tumors [181-184]. The lower edema fraction 
of A431 tumors indicates more cellularly dense tumors as compared to NCI-H1975 
tumors. The drug has also been known to exert a limited bystander effect [185]. Overall 
higher levels of baseline hypoxia may indicate poorer perfusion, leading to lower 
transport of the pro-drug and hence reduced efficacy.  
The determinants of HAP efficacy have been discussed in detail in section 1.1.3. 
It is also important to identify the expression of reductases to predict sensitivity of the 
tumor cells to the effector. Analysis for the presence of these reductases in A431 and 
NCI-H1975 cell lines would assist in analyzing the response and correlate with the results 
obtained. The efficacy of HAP is also dependent on the half-life of the cytotoxic 
counterpart. A longer half-life would enable the effector to target more regions in the 
tumors before being metabolized and excreted. The effector should have high potency 
and ability to kill cells in different pH and different cell cycles states such as proliferating 
as well as non-proliferating, which are predominantly present in the hypoxic regions.  
Therapy induced changes in oxygenation are an important factor for examining 
treatment effect. Previous studies have shown that treatment with EGFR-TKIs geftinib 
and erlotinib resulted in tumor regression as well as a decrease in hypoxia in NSCLC 
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tumors [173, 186]. PR509 inhibits the proliferation and differentiation in the tumors 
expressing the EGFR family of tyrosine kinase receptors, thereby resulting in the tumor 
regression in some tumor models. EGFR has been shown to regulate angiogenesis [92, 
187] and thus inhibition of EGFR via PR509 might explain the reduction in oxygenation 
post PR509 therapy in NCI-H1975 tumors and no significant improvement in the 
oxygenation of A431 tumors.  
 In NCI-H1975, the TPZ treatment resulted in a significant decrease in the 
oxygenation of tumor centers at day 5 and day 10 post-treatment, which is in agreement 
with the previous studies that show tirapazamine causes vascular shutdown in the center 
of the tumor [188-191]. This pattern was further validated by the significantly higher 
hypoxic fraction (obtained from pimonidazole staining) in TPZ treated NCI-H1975 
tumors as compared to the untreated control. The successful treatment with PR509 and its 
effector resulted in an increase in the oxygenation of A431 tumors. While in NCI-H1975 
tumors, PR509 resulted in maintaining the oxygenation of tumor centers and a significant 
increase in the tumor periphery. On the other hand, PR509E treated tumors had a 
reduction in the oxygenation of tumor centers at day 15 post-treatment.  
With the use of the PISTOL technique we were able to determine the baseline 
levels of oxygenation and the intra-tumoral heterogeneity in tumor. The technique was 
also successful in determining the therapy-induced changes in tumor oxygenation can 
differentiate between the different levels of hypoxia. Pimonidazole is considered to be a 
gold-standard for hypoxia and thus we analyzed the distribution of hypoxia post-therapy. 
The hypoxic fractions obtained from IHC cannot be used to differentiate between mild 
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hypoxia, severe hypoxia and anoxia. Pimonidazole is limited to the tumor regions that are 
well perfused and thus might fail to generate an accurate map of distribution of hypoxia.  
A potential limitation of our current PISTOL probe is that pO2 measurements can 
only be extracted from the regions that contain HMDSO droplets, which might not 
represent the oxygenation of the entire tumor. Keeping this limitation in mind we aimed 
at depositing the HMDSO droplets uniformly at a single plane in the tumor. The 
significant differences observed in the center vs. periphery of the tumors suggest that this 
method was able to report the heterogeneity in the tumors. There is also a possibility that 
HMDSO droplets might fall in the anoxic or necrotic regions of the tumor, affecting the 
measured mean pO2, thus it is necessary to consider this experimental limitation and 
exclude pO2 measurements from such regions in future.  
The results obtained so far show us that there not a direct correlation between 
HAP efficacy and occurrence of hypoxia. Identification of predictive hypoxic biomarkers 
in individual patients is critical in designing a treatment plan and evaluating response of 
HAP therapies. Given the heterogeneity of hypoxia and perfusion in different tumor types 
and also within different patients, there is need for improved stratification strategies and 
also for development of novel and better hypoxia targeted/activated therapeutics. 
Screening of multiple tumor models for hypoxia and their response to the HAPs is 
necessary in planning therapies and development of better therapeutics. The parameters 
such as oxygen consumption and its dependence on pO2 measured for various cancer cell 
types add to our understanding of the metabolic consequences of cancer progression and 
provide an opportunity to engineer new therapeutics.  
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CHAPTER 3 
QUALITATIVE MRI ASSESSMENT OF CHANGES IN TUMOR HYPOXIA POST 
HYPOXIA-TARGETED THERAPY USING A NOVEL HYPOXIA-TARGETING T1 
CONTRAST AGENT-GdDO3NI 
 
3.1 Abstract 
The goal of this study was to investigate the potential of GdDO3NI in generating 
high-resolution maps of tumor hypoxia before and after administration of hypoxia 
activated therapy. The r1 and r2 relaxivities of GdDO3NI at 7 T were measured to be 4.75 
± 0.04 mM
-1
 s
-1
 and 7.52 ± 0.07 mM
-1
 s
-1
 respectively, in deionized water. GdDO3NI was 
able to report the baseline distribution and intensity of hypoxia in non-small cell lung 
cancer xenograft models (NCI-H1975) as well as a response to the hypoxia activated pro-
drug tirapazamine. Heterogeneous distribution of hypoxia was found within the NSCLC 
tumors. The agent was able to differentiate between the hypoxic vs. normoxic regions in 
the tumor. NCI-H1975 tumors had a hypoxic fraction of 0.48 ± 0.28 and a normoxic 
fraction of 0.45 ± 0.26. The baseline mean percentage enhancement (i.e. the hypoxic 
intensity) was found to be 23% ± 6.5%. Tirapzamine was effective in slowing down the 
growth in treated tumors as compared to the untreated control tumors (p<0.05). An 
increased distribution of hypoxia was observed post Tirapzamine treatment as compared 
to the untreated control tumors (p<0.05). Furthermore, a significant increase was 
observed in the hypoxic intensity of untreated control tumors from baseline. GdDO3NI is 
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therefore a promising hypoxia imaging agent for detection and evaluating the 
modulations of hypoxia non-invasively and longitudinally.  
3.2 Introduction 
Hypoxia is a physiological condition associated with various pathologies, 
including cancer, ischemic heart disease, peripheral vascular disease and stroke [192]. 
Given that hypoxia is a prominent contributor toward tumor growth and therapeutic 
resistance, it is important to evaluate the presence, distribution and degree of hypoxia 
before and after therapeutic interventions. A hypoxia mapping technique that can provide 
accurate three-dimensional maps of degree and distribution of hypoxia non-invasively 
and in real time could assist clinicians in therapy planning and potentially improve the 
treatment outcome.  
Despite advances in imaging techniques, there is still a lack of an efficient 
hypoxia imaging technique that can provide accurate, high-resolution 3-D distribution 
and intensity maps of hypoxia longitudinally and non-invasively in the clinical setting. 
Hypoxia is highly variable throughout the tumor and information about its location and 
intensity in the tumors can assist clinicians in determining the radiation dosage, region of 
maximum impact and also drug combinations to improve therapy outcome. As a 3D 
hypoxia mapping agent [152], GdDO3NI has the potential to provide accurate maps of 
the distribution and severity of hypoxia before and after therapeutic interventions. 
Preliminary in-vivo studies carried out on nu\nu mice implanted subcutaneously with 
NCI-H1975 (NSCLC) tumor cell line demonstrated the efficacy of GdDO3NI in 
reporting regions of hypoxia when compared with the gold-standard pimonidazole. 
64 
 
Briefly, 1 mm thick T1-weighted images were acquired pre and post intra-peritoneal 
injection of 0.3 mmol\kg body weight GdDO3NI for every 5 minutes up to 130 minutes 
post injection to a total time of 150 minutes. Pimonidazole was used as an ex-vivo marker 
for hypoxia and tumors were harvested for IHC staining.  A single MR percentage 
enhancement image corresponding to the pimonidazole stained image was co-registered. 
R
2
 values between the tumor boundaries and hypoxia boundaries were then determined 
using custom MATLAB code to determine the degree of correlation for the images. 
When registered, the tumor boundaries yielded R
2
 values of 0.9034 and hypoxia-
thresholded R
2
 values of 0.4752 (figure 3.1). The preliminary results motivated us to 
investigate the baseline heterogeneity in NCI-H1975 tumors and their response to TPZ 
treatment via GdDO3NI and compare the results with PISTOL analysis.  
 
 
Figure 3.1: Co-Registration and hypoxic thresholding of IHC and MR percentage 
enhancement images.  
 
65 
 
3.3 Materials and Methods: 
The GdDOTA monoamide conjugate of 2-nitroimidazole, GdDO3NI (molecular 
weight 0.912 kD), was prepared as previously described [147]. All the MR Studies were 
performed on a Bruker BioSpec 7 Tesla (7 T) preclinical scanner (Bruker BioSpin 
Corporation, USA).  
3.3.1 Relaxivity measurements 
The in-vitro relaxivity studies were conducted at bore temperature (~23.6 
0
C) and 37 
0
C. 
Serial dilution phantoms of GdDO3NI (0-2mM) in deionized water (DI) were prepared. 
The solutions (100 µl) were added to a 96 well plate that was cut into a 4 × 2 grid and 
placed inside the magnet on a heated water bed. A volume trans/receiver coil was used to 
conduct the imaging. The temperature of the phantoms was monitored using a fiber optic 
probe. A RARE T1 mapping sequence with a variable TR ranging between 148 ms and 5 
s (total 10 TR times) and a TE of 11 ms was used to determine the T1 of the samples. A 
MSME T2 mapping sequence with a variable TE ranging between 11-330 ms (total 30 
TEs) and a TR of 2.5 ms was used to determine the T2 of the samples. The relationship 
between Ri (1/Ti) values and contrast agent concentration (eqn. 1.1) was used to 
determine the ri relaxivity of GdDO3NI (where i = 1 or 2). The T1 values were obtained 
at by fitting the acquired T1 maps to a single exponential, three parameter saturation 
recovery equation:  
Mz (t) = M0(1-e
-TR/T1) 
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The T2 values were obtained at by fitting the acquired T2 maps to a single exponential, 
three parameter saturation recovery equation:  
 Mxy(t) = M0 e
−TE/T2 
3.3.2 Animal models 
Human NCI-NCI-H1975 non-small cell lung cancer cells (ATCC Inc.) were 
cultured in Roswell Park Memorial Institute (RPMI 1640) media and Dulbecco’s 
Modified Eagle’s Medium (DMEM) respectively, supplemented with 1% 
penicillin/streptomycin and 10% fetal bovine serum (Life Technologies, Carlsbad, CA, 
USA), in a 5% CO2-containing humidified atmosphere at 37
0
C. Immunocompromised 
nu\nu mice (5-6/per cohort, Charles River Laboratories) were implanted subcutaneously 
with 2x10
6
/40 µl cells of the respective cell line in the right thigh. The animals were 
monitored and maintained as per the guidelines by The Arizona State University 
Institutional Animal Care and Use Committee (IACUC).  
 
3.3.3 Hypoxia activated treatment 
Hypoxia activated pro-drugs have a characteristic hypoxic threshold at which they 
convert into their toxic counterpart. We wanted to examine the correlation between the 
baseline distribution and extent of hypoxia in our tumor model with HAP efficacy. The 
efficacy of hypoxic activated pro-drug tirapazamine (SR 4233) was analyzed in this 
study. TPZ was administered intra-peritoneally at the dosage of 60 µmole/kg/body-
weight in 5 % dextrose to each mouse after the completion of baseline MR imaging.  
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In order to determine the efficacy of treatment, tumor volume measurements were 
made using calipers every 3
rd
 day from the day of baseline imaging and until tumor 
excision (day 5). The formula for an ellipsoid (πabc/6), where a, b and c are three longest 
orthogonal dimensions (with a being the longest), was used to calculate the tumor 
volumes. Tumor volumes were normalized to baseline imaging volumes and then 
compared to study the treatment response.  
 
3.3.4 In-vivo MR imaging 
11 nu/nu mice were imaged in this study to evaluate the efficacy of the GdDO3NI 
in mapping the tumor hypoxia pre and post therapeutic intervention. All the imaging 
procedures were approved by The Arizona State University Institutional Animal Care and 
Use Committee (IACUC). The imaging was done once the tumors reached ~300 mm
3
 in 
volume. The mice were anesthetized (1.5% isoflurane in Air) and placed inside the 
magnet on a circulating heated water bed with a mouse body surface coil positioned on 
the tumor for imaging. The water bed was maintained at 37°C throughout the experiment. 
Multi-slice T1 and T2 maps were acquired pre and post GdDO3NI injection with the 
following parameters: T1 mapping with a variable TR of 0.2 – 5 s (9 TRs) and a TE of 8 
ms and T2 mapping with a variable TE of 8-160 ms (15 TEs) and TR of 3 s (FOV= 2 cm 
× 2 cm, matrix=128 × 64 (RO x PE, reconstructed to 128 x 128), slice thickness = 1 mm, 
resolution 156 µm). The pre-injection T1 and T2 mapping images were followed by 
acquisition of a 3D gradient echo imaging with a TE of 3 ms, TR of 80 ms and an alpha 
of 35º (FOV= 2 cm × 2 cm × 2 cm, matrix=128 × 64 × 64 (RO x PE1 x PE2, reconstructed 
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to 128 x 128 x 128)). Three consecutive multi-slice T1-weighted images (TR/TE = 200/8 
ms, FOV= 2 cm × 2 cm, matrix=128 × 64 (RO x PE reconstructed to 128 x 128), slice 
thickness = 1 mm) were then acquired and were immediately followed by intravenous 
administration of 0.1 mmol/kg/body-weight of GdDO3NI. Serial T1-weighted images 
with the same parameters were acquired every 5 min for a total of 130 min along with 
two 3D gradient echo images at 60 min and 125 min post-GdDO3NI injection (total 24). 
TPZ was administered after the completion of day 0 MR imaging and the same imaging 
protocol was followed at day 5. The following relationship was used to determine the 
concentration of Gd: [Gd] = (R1,post – R1,pre)/r1 , where R1,pre and R1,post are the relaxation 
rates and r1 is the relaxivity of the contrast agent. The spin-echo based signal equation 
was used to compute the concentration of the agent for all the T1-weighted scans.  
 
Figure 3.2: Schematic representation of the study protocol. 
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Figure 3.3: Schematic representation of the imaging protocol. 
3.3.5. Immunohistochemical analysis of hypoxia 
In order to determine the efficacy of GdDO3NI as a hypoxia-imaging agent, we 
compared the hypoxia distribution pattern with that of gold standard pimonidazole. 
Pimonidazole HCL (60 mgs/kg/body-weight (Hypoxyprobe Inc.)) was administered 
simultaneously with GdDO3NI and the tumors were excised immediately after imaging 
and embedded in optimum cutting temperature compound (OCT).  For ex-vivo analysis 
of hypoxia, 30 µm thick tumor sections (30 sections) at the same imaging plane as MR 
were obtained using a cryostat. The tumor section were stained with FITC conjugated 
anti-pimonidazole antibody (1:500) overnight at 4
0
C and counterstained with DAPI (300 
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nM, nucleic acid stain). The stained section were mounted with Vectashield medium 
(Vector Laboratories, Burlingame, CA) and visualized under the DMI 6000B Leica 
Microsystems microscope using the green channel for pimonidazole and the blue channel 
for DAPI at 5X magnification.  
Hypoxic fractions were calculated using a custom made MATLAB code. Briefly, 
the image was split into blue (DAPI) and green (Pimo) channels. The blue channel 
images were used to delineate the tumors and applied to green channel image. A region 
of interest was drawn around a normoxic region in the green channel image and tumor 
regions with intensity 2 standard deviations above the mean intensity of the normoxic 
region were considered as hypoxic and used to calculate the hypoxic fraction. 
 
3.3.6 Edema fraction analysis 
The protocol for this calculation has been discussed in detail in chapter 2 section 
2.3.6. The edema fraction was calculated for both the cohorts before and after treatment. 
The mean baseline edema fraction for the tumors was calculated by pooling all the 
tumors together. 
 
3.3.7 Data analysis 
A region of interest was drawn on a T2-weighted scout image in order to delineate 
the tumor. A mean of three baseline T1-weighted images was computed and used to 
obtain percentage enhancement maps. The regions with percentage enhancement >10% 
as compared to baseline at the 130 min post injection were considered as hypoxic while 
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regions with >10% enhancement at 90s and <10% at 130 min post-injection time point 
were considered normoxic and <10% at 90s and <10% 130 min post-injection were 
considered to be necrotic. Hypoxic fractions for MR images were calculated based on the 
percentage enhancements maps calculates based on baseline and 130 min post-injection 
time point T1-weighted image. The above mentioned threshold for image analysis are 
based on the previous in-vivo studies conducted with GdDO3NI and its untargeted 
counterpart GdDO3ABA (Gd-DOTA-(n-butyl)monoamide, control agent) [151]. The 
analysis of time course changes in signal intensities and contrast agent concentration 
based on a threshold of 10% showed a significantly higher intensity and concentration of 
GdDO3NI than GdDO3ABA in tumors at the late time points (i.e. 130 min post 
injection). A threshold of <10% enhancement was considered to exclude the regions with 
necrosis as the contrast agents are prone to accumulate in those regions over  time via 
passive diffusion [193]. Previous studies were successful in differentiating the regions 
with necrosis based on the threshold as validated with ex-vivo hypoxia imaging using 
pimonidazole [151].  
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Figure 3.4: Representation of the image segmentation procedure for data analysis. (a) 
Tumor region with the ROI applied to delineate tumor from thigh region. (b) The 
percentage enhancement image at (b) 90s and (c) 130 min from the time of injection  
were used to segment the (e) normoxic (% enhancement <10 % at 130 min post injection 
and >10% at 90s post injection) and (f) necrotic regions (% enhancement <10 % at 130 
min post injection and <10% at 90s post injection). (d) The regions with % 
enhancement>10% at 130 post-injection were considered hypoxic.  
 
3.3.8 Image registration 
The efficacy of GdDO3NI in reporting regions of hypoxia were analyzed by a 
voxel by voxel correlation with the pimonidazole stained images of the tumors. The 
mechanism of action for pimonidazole, like other 2-nitroimidazole moiety containing 
agents, is the irreversible reduction into the hydroxylamine. Thiols play an important role 
in the binding of pimonidazole in the hypoxic regions. Pimonidazole binds to thiol 
containing protein such as glutathione and gets trapped in the hypoxic environment.  
A strong correlation between the hypoxic maps obtained by the two imaging 
modalities is indicative of the agent’s efficacy. Regions of interest were drawn on a T2-
weighted image and DAPI stained tumor image, and both the images were registered and 
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the correlation between the ROIs was evaluated using a coefficient of determination, or 
R
2
. With the images adequately registered, voxel-to-voxel comparison was conducted to 
show the correlation between the hypoxia maps. A hypoxic threshold of >10% MR 
enhancement image was used for the MR images and 2 standard deviations above the 
mean of normoxic tissue was used for the pimonidazole stained image to calculate the 
hypoxic fractions. Assuming a normal or Gaussian distribution of the intensity of 
normoxic regions, approximately 95% of the values would fall between the mean and 2 
standard deviation above the mean. Thus choosing a threshold of above the 2 standard 
deviation would ensure efficient determination of regions with hypoxia. In addition, a 
structural similarity index between both modalities was used as another metric for 
establishing the similarity of the images post-thresholding [6], with mean squared error 
also calculated between the two modalities.  
 
3.4 Results 
3.4.1 Baseline tumor hypoxia and edema fraction  
The r1 and r2 relaxivities of GdDO3NI at 7 T were measured to be 4.75 ± 0.04 
mM
-1
 s
-1
 and 7.52 ± 0.07 mM
-1
 s
-1
 respectively, in deionized water at 37 ºC (figure 3.5). 
11 NCI-H1975 tumor-bearing animals were studied, 6 mice were given the TPZ 
treatment and 5 were treated as control (5% dextrose). The mean baseline hypoxic 
fraction and mean percentage enhancement (using GdDO3NI) of the of NCI-H1975 
tumors was found to be 0.48 ± 0.28 and 23% ± 6.5% respectively (figure 3.6 A).  As 
expected the mean percentage enhancement of the normoxic region was significantly 
74 
 
lower at 3.7% ± 4%, but the normoxic fraction was found to be similar to hypoxic 
fraction at 0.45 ± 0.26 (figure 3.6 B). A threshold of 10% and above enhancement from 
the baseline was used to calculate the hypoxic fractions.  The mean baseline edema 
fraction of the tumor model was 0.12 ± 0.03.  
 
Figure 3.5: Relaxivity of GdDO3NI at 7 T, in DI at 37 ºC. 
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Figure 3.6: Baseline distribution and intensity of hypoxia in NCI-H1975 tumors (n =11).  
A correlation analysis between the baseline distribution (figure 3.7 A) and 
severity of hypoxia (figure 3.7 B) with the tumor volumes showed that the presence of 
hypoxia was not dependent on the tumor size.  
 
Figure 3.7: Correlation analysis between baseline characteristics of hypoxia and tumor 
volume. 
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3.4.2 Treatment response 
3.4.2.1 Tumor volume and edema fraction  
The efficacy of the HAP treatment was determined by analyzing the normalized 
mean tumor volume differences between the treated and untreated control cohorts. The 
mean normalized tumor volumes of TPZ treated NCI-H1975 tumors (2.1 ± 0.28) were 
significantly lower than the untreated control tumors (2.7 ± 0.50 p<0.05) at day 5 (figure 
3.8). The treatment resulted in an increase in the edema fraction of TPZ treated tumors at 
day 5 (0.15 ± 0.05) from day 0 (0.11 ± 0.03, p = ns (not-significant)), while the untreated 
control tumors did not show any change in the edema fraction at day 5 (0.12 ± 0.04) from 
day 0 (0.12 ± 0.04) (figure 3.9). 
 
Figure 3.8: Mean of normalized tumor volumes of treated (n =6) and untreated control (n 
= 5) NCI-H1975 tumors (* represents p<0.05). Note: the error bars represents standard 
deviations. 
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Figure 3.9: The edema fraction before and after treatments. Note: the error bars 
represents standard deviations. 
 
3.4.2.2 Treatment effect on hypoxic fraction and intensity 
Hypoxia is an important indicator of the treatment efficacy and the treatment-
induced changes have not been well documented before. I evaluated the changes in mean 
hypoxic fraction and percentage enhancement in the tumors post-treatment. The hypoxic 
fraction between the individual cohorts did not show a significant difference from their 
baseline levels. We observed that TPZ treated tumor had a significantly higher hypoxic 
fraction at day 5 than the untreated control tumors (figure 3.10 A). The mean percentage 
enhancement of the tumors increased for both TPZ and untreated control tumors at day 5, 
although the changes were only significant for untreated control tumors (figure 3.10 B).  
The mean percentage enhancement of TPZ tumors was higher than the untreated control, 
but the difference was not significance (p<0.09).  
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Figure 3.10: The treatment induced changes in distribution and intensity of hypoxia (* 
represents p<0.05). Note: the error bars represents standard deviations. 
 
3.4.3 Kinetics of GdDO3NI in NCI-H1975 tumors 
We investigated the time course changes in the mean percentage enhancement of 
both the cohorts. Figure 3.11 shows the time course changes in the concentration of the 
agent for both hypoxic and normoxic regions of the cohorts. The concentration maps 
were generated from the enhancement maps for each animal pre and post therapy. 
Quantitatively, the peak concentration of the agent was 41 ± 10 µM in TPZ treated 
tumors and a peak concentration of 33 ± 10 µM in untreated control tumors (, p = ns). 
The analysis of time course of Gd concentration showed that the time to reach peak 
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concentration was faster pre-treatment as compared to post treatment for both the 
treatment groups. As, expected the peak concentrations were higher for the normoxic 
regions followed by a rapid clearance of the agent. 
 
Figure 3.11: The kinetics of mean agent concentration for normoxic and hypoxic regions 
in NCI-H1975 tumors. 
Linear fitting of mean concentrations for end time points (100-125 min post 
injection) showed no significant difference between the slopes of hypoxic vs. normoxic 
regions as well as between pre and post treatment hypoxic regions. As expected, linear 
fitting the early time point (15-35 min post injection) Gd concentrations showed a 
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significant difference between the slopes of normoxic vs. hypoxic regions for both the 
treatment groups.  
 
3.4.4 Co-registration of MRI and IHC images 
We analyzed one TPZ-treated and one untreated control tumor for correlation analysis. 
Pimonidazole staining of the NCI-H1975 tumors confirmed the presence of hypoxia 
within the tumors. Because our goal was to compare the hypoxia maps obtained by 
GdDO3NI, we conducted a voxel by voxel comparison between the MR and IHC images 
(figure 3.12). A single 30 µm thick microcopy image was compared with 1 mm thick MR 
percentage enhancement image. The image similarity indices also showed a strong 
correlation for each image, with 0.7295 for H-1975 TPZ treated tumor and 0.6737 for 
untreated control tumor. This is a strong metric for determining how similar two images 
are, taking into consideration luminance, structure, and contrast between images to 
measure image similarity. R
2
 values were also collected for both hypoxic regions as well 
as tumor boundaries, shown in figure 3.12. A high correlation was obtained between the 
boundaries of the DAPI stained image and the corresponding T2 weighted image. The R
2
 
comparisons didn’t show favorably between the hypoxic maps of the modalities as did 
the structural similarity index. Mean-squared errors were very small, however, further 
showing strong correlation between modalities.  
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0.5281 0.4790 0.9391 0.2900 0.6737 0.1208 
TPZ 
treated 
0.6631 0.8127 0.9265 0.5243 0.7295 0.0817 
 
Figure 3.12: The correlation analysis between pimonidazole stained tumors vs. MR 
obtained hypoxia maps.  
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Figure 3.13: Percentage enhancement maps of a single slice of untreated control NCI-
H1975 tumor at 125 minutes post-injection of GdDO3NI with respect to pre-injection 
intensity. The region of interest used to delineate the tumor is shown in the T2 weighted 
reference image.  
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Figure 3.14: Percentage enhancement maps of a single slice from the same NCI-H1975 
untreated tumor (at a distance of 5 mm from the previous slice) at 125 minutes post-
injection of GdDO3NI with respect to pre-injection intensity. The region of interest used 
to delineate the tumor is shown in the T2 weighted reference image. T and M represent 
the tumor and muscle regions.  
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Figure 3.15: Percentage enhancement maps of a single slice of TPZ treated NCI-H1975 
tumor at 125 minutes post-injection of GdDO3NI with respect to pre-injection intensity. 
The region of interest used to delineate the tumor is shown in the T2 weighted reference 
image. T and M represent the tumor and muscle regions. 
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3.5 Discussion 
The hypoxia targeting ability of GdDO3NI has been validated previously in-vitro 
and in-vivo using 9L glioma cells incubated under hypoxia and AT1 xenograft models 
respectively [147, 151]. The goal of this study was to demonstrate the efficacy of our 
hypoxia binding T1 contrast agent GdDO3NI in reporting the distribution and extent of 
tumor hypoxia, evaluate the efficacy of TPZ and its effect over the hypoxia of non-small 
cell lung cancer tumors.  
The non-small cell lung cancer model NCI-H1975 was chosen to be studied as the 
preliminary analysis conducted via GdDO3NI was able to show presence of hypoxia in 
the tumor model. The relaxivity properties of the agent at 7 T were found to be similar to 
the relaxivities obtained at 4.7 T [151] and also to the other conventional Gd based MR 
contrast agents [194]. The slight decrease in T1 relaxivity can be attributed to the increase 
in magnetic field strength.  
We first evaluated the baseline properties of hypoxia within the tumors. NCI-
H1975 tumors had high hypoxic fraction of about 48%, which has been seen in previous 
studies conducted with 
18
F-FMISO or 
18
F-FETNIM [195, 196].  
It is important to note that solid tumors that are grown subcutaneously are prone 
to be more hypoxic than the orthotopic models [30]. The contribution of necrotic regions 
were excluded from all the analysis as the agent is prone to accumulate in those regions 
due to passive diffusion which has been seen by both targeted as well as non-targeted 
contrast agents [193]. HAPs impart their toxicity to hypoxic cells by converting into their 
toxic counterpart in the presence of hypoxia, thus baseline oxygenation of the tumors 
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could aid in predicting the therapeutic response. TPZ treatment resulted in a significant 
decrease in tumor growth as compared to the untreated control, which is consistent with 
the observation of baseline hypoxia within the NCI-H1975 tumors. 
Therapeutic modulation of tumor hypoxia is an important indicator for therapy 
effect and the changes have not been well studied. The hypoxic fraction results indicate 
an increase in the distribution of hypoxia within the tumors post TPZ as well as untreated 
control tumors. Several studies have documented that effective TPZ treatment results in 
vascular shutdown in xenograft models of tumors, resulting in increased hypoxia in the 
central regions of the tumors [188-191]. TPZ gets converted into its toxic counterpart at 
relatively moderate hypoxia, thus tumors with higher distribution of moderate hypoxia 
have the inclination to be more responsive to TPZ treatment. 
The variations in the retention of GdDO3NI in tumor regions represent the 
heterogeneity in the severity of hypoxia (as reflected in mean agent concentrations). 
GdDO3NI was able to report the treatment induced changes in severity of hypoxia post 
treatment. Untreated control tumors had a significant increase in the severity of hypoxia 
(p<0.05), but no significant difference in the distribution of hypoxia. It is important to 
note that the TPZ resulted in significantly more regions of hypoxia than the untreated 
control (p<0.05) and a higher percentage enhancement but the difference was not 
statistically significant for the latter (p<0.09).  
The time course evolution of mean percentage enhancement and derived 
concentrations indicate a delay in accumulation and higher retention of the agent in the 
hypoxic regions as compared to the normoxic regions. Normoxic regions show faster 
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accumulation for both pre and post-treatment time points and a fast wash-out. The slower 
buildup of the GdDO3NI in hypoxic regions is similar to the kinetics of other targeted 
contrast agents [197].  
In order to validate the efficacy of GdDO3NI in reporting regions of hypoxia, I 
decided to carry out a correlation analysis of MR percentage enhancement images with 
pimonidazole stained images of the tumors. Pimonidazole is a gold-standard hypoxia 
marker that is extensively used in the clinic to detect regions of hypoxia [119]. It also 
contains the 2-nitroimidazole moiety and has a hypoxia binding threshold of <10 torr. 
Pimonidazole staining confirmed the presence of hypoxia within the tumors which is 
consistent with the hypoxia maps obtained from MR enhancement images. The 
correlation between MR hypoxic fractions and pimonidazole hypoxic fraction on a whole 
tumor level showed much lower R
2
 values are much smaller than expected. However, this 
might be due to the difference in slice thickness between the modalities (1mm for MRI, 
30 µm for IHC). The discrepancies in the amount of tissue imaged between the two 
modalities might lead to significant mismatch in hypoxia assessment between the two 
techniques.  Visually, the hypoxia distribution pattern correlates between the 
pimonidazole images and GdDO3NI contrast enhancement maps obtained and highlight 
the agent’s ability to effectively report regions of hypoxia. Future work will involve the 
collection of serial sections of tumor tissues ex-vivo and reconstruction of tumor volume 
corresponding to the thickness of MR images.  
Targeted, non-invasive in-vivo imaging of hypoxia using GdDO3NI has the 
potential to determine regions with poor oxygenation and differentiate between normoxic 
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vs. hypoxic tissues. The response of NCI-H1975 tumors to TPZ treatment was in 
agreement with the baseline distribution of hypoxia as detected by GdDO3NI.  A higher 
resolution imaging of tumor oxygenation is preferable for imaging the spatial 
heterogeneity of hypoxia which might vary even at smaller distances of <150 µm. MRI 
can facilitate acquisition of higher resolution 2D images but with longer acquisition 
times. The clinical imaging with PET is mostly acquired at a resolution of 5 mm and 
recent developments have led to acquisition at 1 mm resolution [198, 199]. In the current 
study, we were able to acquire multi-slice T1 weighted images and 3D gradient echo 
images at a high resolution of 156 µm which is better suited for evaluating the 
heterogeneity in tumor hypoxia. GdDO3NI has shown the ability to bind to hypoxic 
regions in both well and poorly perfused regions of a tumor. The agent can also be 
utilized to monitor the behavior of tumor hypoxia as a response to hyperoxic breathing 
for patient stratification. The voxel-by voxel analysis of GdDO3NI kinetics can provide 
crucial information regarding the tumor’s perfusion. Further advancement in the 
understanding of contrast kinetics of the agent can facilitate extraction of quantitative pO2 
values and differentiate between the mild, moderate and severe levels of hypoxia. 
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CHAPTER 4 
 
MRI ASSESSMENT OF CHANGES IN HYPOXIA AND OXYGENATION IN 
PATIENT DERIVED XENOGRAFT MODELS OF NSCLC POST HYPOXIA 
ACTIVATED THERAPY 
 
4.1 Abstract 
The development and screening of novel hypoxia activated therapeutics rely on 
tumor models that can represent the same microenvironmental conditions as seen 
clinically. Patient derived xenograft models have emerged as an improved platform for 
pre-clinical evaluation of tumor properties (such genomic and phenotypic markers) and 
the pharmacokinetics and pharmacodynamics of novel drugs. The goal of the current 
study was to examine the hypoxic environment of two different non-small cell lung 
cancer PDX models and their response to hypoxia activated pro-drug, tirapazamine. The 
efficacy of both PISTOL and GdDO3NI as hypoxia imaging techniques were examined 
and compared. The M112004 PDX models had significantly higher baseline hypoxia than 
the M1005 PDX model (p<0.01) as measured by PISTOL and GdDO3NI. The 
tirapazamine treatment resulted in an increase in extent and severity of hypoxia in the 
M1005 tumors (p<0.05). The application of both the oximetry techniques has the 
advantage of providing functional and physiological information of hypoxia that can 
benefit the scientific community in improving the treatment protocol.  
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4.2 Introduction 
Animal models of rodents with compromised immune system are routinely used 
in pre-clinical studies to screen novel chemotherapeutic agents for their toxicity, efficacy 
and pharmacokinetics [200-203].  The subcutaneous xenograft models of established cell 
lines have been the most studied models in-vivo because of their ease of development and 
extensive genetic information available, but they lack the relevant heterogeneity in 
mutations and sub-population of tumor cell types that are present in a patient’s tumor 
[204, 205]. Thus, these models might fail in representing the clinical therapeutic 
response. The failure of recent promising HAPs in the clinical trials have called for 
inclusion of patient stratification strategies based on hypoxia and also for improved pre-
clinical tumor models that can faithfully replicate the environment and characteristics of a 
clinical tumor. Patient derived xenograft models are developed by extracting tumor 
fragments from a patient’s tumor and propagating them in rodent models, thus 
eliminating the 2D growth cycle which removes the selection bias that 2D cell culture go 
through. Patient derived xenograft models retain the genetic mutations and phenotypic 
heterogeneity of the parent patient tumor [205-209]. They also represent the tumor 
vasculature, invasiveness, metastatic potential, morphology, molecular markers and 
cellular diversity of the tumor [203, 210-214]. Thus, patient derived xenograft models are 
better suited for pre-clinical evaluation of tumor properties.  
I have previously reported the behavior of a NCI-H1975 cell line based model of 
NSCLC before and after tirapazamine intervention in chapters 2 and 3. Given the 
importance of tumor microenvironment and its components in defining the effect of a 
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treatment, we decided to evaluate the baseline oxygenation of NSCLC PDXs in-vivo and 
their response to the tirapazamine. Multi-modality imaging of hypoxia has the advantage 
of generating a more comprehensive analysis of tumor hypoxia by combining the 
strengths of two complimentary imaging techniques, e.g. PET imaging agents combined 
with quantitative assessment of hypoxia via polarographic needle electrodes [114, 199, 
215-218] The hypoxia binding contrast agent GdDO3NI and oxygenation mapping 
technique PISTOL (Proton Imaging of Siloxanes to Map Tissue Oxygenation Level) have 
shown the efficacy in reporting regions of hypoxia qualitatively and quantitatively 
respectively. The combined assessment of oxygenation via GdDO3NI and PISTOL has 
the potential to provide a more detailed representation of hypoxia that can be used for 
better treatment planning. In this chapter I report the baseline expression of hypoxia in 
PDX models of NSCLC and their response to tirapazamine treatment via PISTOL and 
GdDO3NI imaging.  
 
4.3 Materials and Methods 
The MRI contrast agent GdDO3NI was prepared as published previously [147, 
151]. All the MR Studies were performed on a Bruker BioSpec 7 Tesla (7 T) preclinical 
scanner (Bruker BioSpin Corporation, USA).  
4.3.1 Animal models 
Human non-small cell lung cancer PDX models M112004 and M1005 were 
provided by Dr. Landon J. Inge (Assistant Professor Norton Thoracic Institute, St. 
Joseph's Hospital and Medical Center, Phoenix, AZ USA). The PDX models were 
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passaged in immunocompromised nu/nu mice by implanting tumor chunks of the 
respective tumor model subcutaneously. The tumors were then extracted and ground 
using a tissue grinder to form a homogenous tumor slurry and 100 µl of the slurry was 
implanted subcutaneously in two cohorts of 10 immunocompromised nu/nu mice for each 
PDX model (therefore 20 mice for each PDX model in total).  The animals were 
monitored and maintained as per the guidelines by The Arizona State University 
Institutional Animal Care and Use Committee (IACUC).   
The NSCLC PDXs were derived from patient tumors collected under an IRB 
approved protocol (#07HL029) at St. Joseph’s Hospital and Medical Center.  NSCLC 
PDXs (M1005, M112004) were derived from patients without evidence of metastatic 
disease and previous treatment, undergoing routine resection [219].  
 
4.3.2 Hypoxia activated treatment 
As stated in earlier studies it is important to examine the correlation between the 
baseline levels of hypoxia in our tumor model with HAP efficacy. The efficacy of 
hypoxic activated pro-drug tirapazamine (SR 4233) was analyzed in this study. TPZ was 
administered intraperitoneally at the dosage of 60 µmole/kg/body-weight in 5% dextrose 
to each mouse after the completion of baseline MR imaging. 5% dextrose was 
administered to the untreated control cohort. Tumor volume measurements were made 
and analyzed using the same protocol described in chapter 2 and 3.  
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4.3.3 MR imaging protocol 
The imaging was conducted on the mice once the tumors reached ~300 mm
3
 in 
volume. The following imaging protocol was followed for both the tumor models: 
Baseline (day 0) PISTOL maps were acquired by following the same protocol as 
described in chapter 2. Briefly, neat HMDSO (Sigma Aldrich., 10-50 μL) droplets were 
deposited in a fan pattern along a single plane in the tumors and mice were then placed 
on a mouse bed. A mouse surface receiver coil was placed over the tumor. The body 
temperature of mice was maintained by keeping them on a heated water-bed at 37
0
C.  Pre 
GdDO3NI injection multi-slice T1 and T2 maps were acquired with the following 
parameters: T1 mapping with a variable TR of 0.2 s – 5 s (9 TRs) and a TE of 8 ms and 
T2 mapping with a variable TE of 8-160 ms (15 TEs) and TR of 3 s (FOV= 2 cm × 2 cm, 
matrix=128 × 64 (RO x PE, reconstructed to 128 x 128), slice thickness = 1 mm, 
resolution 156 µm). Three consecutive PISTOL T1 maps were then acquired followed by 
acquisition of a 3D gradient echo imaging with a TE of 3 ms, TR of 80 ms and an alpha 
of 35º (FOV= 2 cm × 2 cm × 2 cm, matrix=128 × 64 × 64 (RO x PE1 x PE2, reconstructed 
to 128 x 128 x 128)).  Three consecutive multi-slice T1-weighted images (TR/TE = 200/8 
ms, FOV= 2 cm × 2 cm, matrix=128 × 64 (RO x PE reconstructed to 128 x 128), slice 
thickness = 1 mm) were then acquired and were immediately followed by intravenous 
administration of 0.1 mmol/kg/body-weight of GdDO3NI. T1-weighted images with the 
same parameters were then acquired every 5 min for a total of 130 min. Two 3D gradient 
echo images were acquired at 60 min and 125 min post-GdDO3NI injection. Post 
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injection T1 and T2 maps were acquired with the same imaging parameters as pre-
injection. At the end of the day 0 imaging protocol, respective therapy (TPZ or 5% 
dextrose) was injected intraperitoneally. Pimonidazole HCL (60 mgs/kg/body-weight 
(Hypoxyprobe Inc, Burlington, Massachusetts, USA)) was administered along with 
GdDO3NI on day 5.  
 
 
Figure 4.1: Schematic representation of the imaging protocol.  
 
4.3.4 Data analysis 
The oxygenation maps from the PISTOL sequence were obtained via the same 
procedure as described in chapter 2. The pre and post GdDO3NI MR images were also 
analyzed as described in chapter 3. Edema fraction analysis was also conducted via the 
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same protocol. For statistical analysis, t-tests (unpaired or paired) were used and an alpha 
of <0.05 was considered significant. 
4.4 Results 
4.4.1 Baseline tumor oxygenation and edema fraction  
18 M1005 and 14 M112004 tumor-bearing animals were studied in total using 
PISTOL technique. The M1005 tumors had a mean baseline oxygenation of 43 ± 16 torr, 
similar to the mean baseline oxygenation of M112004 tumors at 47 ± 10 torr (figure 4.2). 
The tumors were segmented into center and periphery based on the T2 weighted images. 
The M112004 tumors had higher baseline intra-tumor heterogeneity in the tumor 
oxygenation with center being more hypoxic than the periphery, while M1005 tumors 
had similar oxygenation throughout the tumor. The hypoxic fraction (a measure of 
distribution of hypoxia) of the M1005 (0.59 ± 0.21) and M112004 (0.70 ± 0.29) tumors 
were similar (figure 4.3 B). Due to unforeseen loss of few mice with M112004 tumors 
resulted in a small sample size for the GdDO3NI imaging (n = 2 for untreated control and 
n = 4 for TPZ treated). A threshold of 10% and above enhancement from the baseline 
was used to calculate the hypoxic fractions. The mean hypoxic intensity (i.e. mean 
percentage enhancement >10%) analysis showed that M112004 tumors (30 ± 9%) were 
significantly more hypoxic than the M1005 tumors (19 ± 3%, p<0.01, (figure 4.3 A)). 
The comparison between the baseline oxygenation of tumor centers of both the PDXs 
also confirmed the observation with M112004 (38 ± 17 torr) having significantly lower 
oxygenation than the M1005 tumors (47 ± 14 torr). M112004 (0.14 ± 0.08) had 
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significantly higher mean baseline edema fraction than the M1005 tumors (0.08 ± 0.03, 
p<0.01, (figure 4.4)).  
 
Figure 4.2: Baseline mean oxygenation of M112004 (n = 14) and M1005 PDX tumors (n 
= 18, * represents p<0.05 and *** represent p<0.001). Note: the error bars represents 
standard deviations. 
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Figure 4.3: The baseline distribution and intensity of M112004 (n = 6) and M1005 PDX 
tumors (n = 11, ** represents p<0.01). Note: the error bars represents standard deviations. 
 
Figure 4.4: Baseline mean edema fraction of M112004 (n = 14) and M1005 PDX tumors 
(n = 16, ** represents p<0.01). Note: the error bars represents standard deviations. 
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4.4.2 Treatment response 
 
4.4.2.1 Tumor volume and edema fraction 
The efficacy of HAP treatment was evaluated by comparing the tumor volumes 
pre and post treatment as well as changes in the baseline oxygenation. The mean 
normalized tumor volumes of both the TPZ treated PDX tumors were not significantly 
different than the untreated control tumors (figure 4.5). No significant changes were 
observed in the edema fraction too for both the PDX models (figure 4.6).  
 
Figure 4.5: The mean of normalized tumor volumes post-treatment of M112004 and 
M1005 PDX tumors. Note: the error bars represents standard deviations. 
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Figure 4.6: The mean edema fraction post-treatment of M112004 and M1005 PDX 
tumors. Note: the error bars represents standard deviations. 
 
4.4.2.2 Treatment induced changes in oxygenation 
Because our goal was to investigate the treatment induced changes in 
oxygenation, we compared the mean oxygenation between pre and post treatment. The 
untreated control M1005 and M112004 tumors did not show any significant changes in 
the mean oxygenation from baseline (figure 4.7 (A) and figure 4.8 (A) respectively). The 
center of TPZ treated M1005 tumors showed a significant decrease in the oxygenation 
from baseline (figure 4.7 B) while M112004 tumors showed no significant changes from 
the baseline (figure 4.8 B).  
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The comparison between oxygenation of center and periphery post-treatment to 
evaluate intra-tumor heterogeneity showed that the centers of M112004 untreated control 
tumors were significantly more hypoxic than the periphery (figure 4.8 A). The M1005 
untreated control tumors also had lower oxygenation in the tumor centers as compared to 
the periphery, but the difference was only close to significance (p<0.06, figure 4.7 A).  
 
Figure 4.7: The changes in oxygenation post therapy in M1005 PDX tumors (* represents 
p<0.05). Note: the error bars represents standard deviations. 
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Figure 4.8: The changes in oxygenation post therapy in M112004 PDX tumors (* 
represents p<0.05). Note: the error bars represents standard deviations. 
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Table 4.1: Mean oxygenation of M112004 and M1005 PDX tumor models pre and post-
treatment.  
Tumor Model Treatment  Mean pO2 (torr) 
 Day 0 Day 5 
M112004  
Untreated Control 
(n = 6) 
Mean 50 ± 18 33 ±11 
Center 45 ± 21 32 ± 10 
Periphery 58 ± 18 37 ± 10* 
 
TPZ 
(n = 8) 
Mean 38 ± 13 30 ± 7 
Center 32 ± 11 29 ± 9 
Periphery 51 ± 18 35 ± 11 
M1005  
Untreated Control 
(n = 8) 
Mean 49 ± 14 43 ± 10 
Center 50 ± 19 40 ± 10 
Periphery 49 ± 16 47 ± 11 
 
TPZ 
(n = 10) 
Mean 46 ± 7 35 ± 8 
Center 45 ± 9 33 ± 10 
Periphery 48 ± 11 40 ± 12 
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4.4.2.3 Hypoxic fraction and intensity  
Next, I analyzed the hypoxic fraction and mean percentage enhancement of the 
treated and untreated control PDX models to evaluate the treatment induced changes in 
the entire tumor. While PISTOL is efficient in providing the quantitative information, it 
is limited to the regions receiving the HMDSO droplets. No significant difference was 
observed in the distribution of hypoxia in M112004 tumors post-therapy (figure 4.9 A). 
The TPZ treatment of M1005 tumors resulted in significant increase in the hypoxic 
fraction of the tumors, while no significant difference was observed in the untreated 
control tumors (figure 4.9 B).  
 
Figure 4.9: The changes in hypoxic fraction post therapy in M112004 and M1005 PDX 
tumors (Untreated control and TPZ treated M1005 n = 5 and 6 respectively, untreated 
control and TPZ treated M112004 n = 2 and 4 respectively).  
 
The mean percentage enhancement for M1005 tumors treated with TPZ increased 
from their baseline levels, although the difference was only close to significance (p<0.08, 
figure 4.10 B). The comparison between the PDX cohorts (i.e. TPZ/Untreated control-
M1005 vs. TPZ/ Untreated control -M112004) showed no significant differences, which 
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means that the distribution and severity of hypoxia were similar for both the tumor 
models post therapy.  
 
Figure 4.10: The changes in hypoxic intensity post therapy in M112004 and M1005 PDX 
tumors (Untreated control and TPZ treated M1005 n = 5 and 6 respectively, untreated 
control and TPZ treated M112004 n = 2 and 4 respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
4.5 Discussion 
The constituents of the tumor stroma are a key contributor towards the 
development of tumor microenvironment and play a major role in promoting 
proliferation, invasion, angiogenesis, and metastasis and also in response to therapy [15, 
220]. The tumor stromal components and the induced microenvironment differ 
significantly between different tumor types, tumor grades and might also differ between 
different patients with the same tumor type. The NSCLC tumors in humans have a 
cocktail of mutations that are unique to each patient’s tumor [221, 222]. These mutations 
are relevant in determining the therapeutic efficacy of targeted drugs that are dependent 
on the expression of molecular targets for imparting toxicity. The PDX models maintain 
the mutation characteristics of the clinical tumors, thus the drug efficacy can be expected 
to closely resemble that seen in clinical studies. Previous studies have shown that PDX 
models were able to replicate the chemotherapeutic responses as seen in parent tumor 
[212, 223, 224].  
The goal of this study was to investigate the behavior of two different patient 
derived xenograft models of non-small cell lung cancer (M112004 and M1005), that 
showed resistance to conventional therapies, as a response to hypoxia activated therapy 
tirapazamine. The changes in distribution and severity of hypoxia therapy were studied 
via both quantitative and qualitative oximetry techniques, simultaneously.  
The oximetry studies via PISTOL and GdDO3NI showed that M112004 were 
more hypoxic and had more intra-tumor heterogeneity than M1005. The higher edema 
fraction points towards higher fluid build-up in the tumors and lack of vasculature in 
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poorly-differentiation M112004 tumors as compared to the well-differentiated M1005 
tumors [219]. 
M1005 tumors were more responsive towards the TPZ treatment than M112004 
tumors. Ideally, we would expect tumors with higher oxygenation to be less responsive to 
the hypoxia activated therapeutics and vice a versa. Tumors with severe hypoxia or larger 
tumor volumes might exacerbate the penetration of TPZ into the central regions of the 
tumors. The tumor centers of M112004 were more hypoxic than the periphery, which 
might result in the inability of TPZ to reach the more hypoxic and aggressive regions of 
the tumor. As discussed before, TPZ has a mild hypoxia activation threshold and suffers 
from a poor bystander effect.  But as discussed in detail before, the presence of hypoxia is 
not the only factor responsible for governing the treatment efficacy. Hypoxic regions are 
known to be distributed throughout the tumor, but not all the regions equally contribute to 
the treatment resistance, thus is it important to locate the treatment limiting hypoxic 
regions of the tumor that provide a niche for the more aggressive phenotype and cancer 
stem cells.  
We would expect a higher efficacy of the drug TPZ in M112004 tumors, but the 
tumors were completely un-responsive to TPZ. Results have also shown that TPZ does 
not work well with dense tumor models as its early metabolism due to mild activation 
threshold in the low density hypoxic regions compromises its penetration towards more 
hypoxic regions. The post-TPZ treatment reduction in the oxygenation in M1005 tumor 
centers might be due to the vascular disruptive nature of TPZ. There was a decrease in 
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oxygenation and also an increase in the regions with hypoxia in M1005 tumors post TPZ 
therapy.  
Because the goal was to investigate the differences between the hypoxic 
behaviors of PDX models vs. the established cell line model, we compared the 
oxygenation data between NCI-H1975 and the PDXs. No significant differences were 
observed in the distribution of hypoxia between the NCI-H1975 and PDX models. 
Quantitative oxygenation data showed that M112004 tumor centers were found to be 
more hypoxic than the NCI-H1975 tumors.  
These results show that the complexity of the tumor microenvironment and its 
interaction with HAPs is a multifactor process. The incidence of hypoxia, its severity, its 
effect on the treatment resistance and tumor progression needs to be evaluated for 
efficient treatment planning. As discussed in chapter 2, the efficacy of any HAP is 
dependent on several factors. Molecular profiling of both the tumor models will give an 
idea of all the genetic mutations that could be relevant to predicting the outcome of HAP 
therapies that target specific molecular markers. The PDX models are an excellent 
platform to test the novel therapeutics, test the different combinatorial treatment protocols 
and for novel drug designing due to their ability to maintain the clinical genetic and 
phenotypic state of the tumor. Studies conducted in pancreatic tumor xenografts in both 
subcutaneous and orthotopic models showed unusually high levels of hypoxia in 
subcutaneous models as compared to orthotopic models [225].  Studies have also shown 
that the response of tumors against therapies was dependent on the location and 
microenvironment of the tumor [226, 227]. It is important to note that the genetic 
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framework of a tumor results in the characteristic tumor microenvironment, thus PDX 
models are an efficient model for replicating the interaction of the HAP with the tumors. 
But the lack of an efficient vascular network and immune response are some of the 
limitations faced by subcutaneous models grown in immunocompromised mice. The 
relationship between the incidence of hypoxia and immune response are still being 
understood. Thus, orthotopic tumor models with clinically relevant expression of hypoxia 
and tumor vasculature might be a better platform than subcutaneous models for 
evaluating the novel HAPs.  
Our study shows that the combined application of PISTOL and GdDO3NI has the 
potential to provide quantitative and qualitative oxygenation data of a tumor which can 
aid in selecting and categorizing patients based on their hypoxic distribution and severity, 
for designing of better therapeutic protocol based on the tumor’s response and for 
determining the optimum time and region of impact for maximum outcome of radiation 
therapy. 
 
 
 
 
 
 
 
 
109 
 
CHAPTER 5 
CONCLUSIONS & FUTURE DIRECTIONS 
Cancer is a ‘rogue’ organ with its own unique microenvironment, molecular 
markers, signaling pathways and organization of vasculature that have all been 
transformed to promote its growth [4]. Since hypoxia plays an important role on the 
tumor progression and disease resistance, it is important to develop and evaluate hypoxia 
targeting and imaging techniques that can improve the clinical therapeutic response. The 
primary goal of these studies was to test the hypothesis that prospective identification of 
hypoxic tumors is important in predicting the therapeutic response and for development 
of personalized treatment protocols. I analyzed the baseline characteristics of hypoxia in 
pre-clinical models of human cancer using two MRI oximetry techniques unique to our 
lab (GdDO3NI and PISTOL) and monitored their response to hypoxia activated therapy 
in terms of tumor size and changes in oxygenation.  
First, I investigated the efficacy of a novel HAP called PR509, its effector 
PR509E and tirapazamine in tumor xenograft models of non-small cell lung cancer (NCI-
H1975) and epidermoid carcinoma (A431). I used the recently developed PISTOL 
technique to map the tumor’s baseline oxygenation and the therapy-induced changes. A 
lower baseline oxygenation in A431 as well as higher intra-tumor heterogeneity in the 
distribution of hypoxia was observed as compared to NCI-H1975 tumors. The treatment 
efficacy of PR509 was in agreement with the expression profile of EGFRs in NCI-H1975 
(mutated EGFR) and A431 (wild-type EGFR) as well as with the baseline expression of 
hypoxia. The effects demonstrated the importance of evaluating the sensitivity of the 
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tumors towards the effector as well as the ability of HAPs to impart toxicity to the 
treatment limiting and tumor promoting sub-population of the tumor cells. Next, I 
reported the ability of GdDO3NI in mapping the distribution and extent of hypoxia in 
NCI-H1975 and two NSCLC patient derived xenograft models M1005 and M112004 
tumors as a response to TPZ treatment. The agent showed r1 relaxivity comparable to 
other clinical contrast agents at 7 T [194].Since hypoxia imaging with GdDO3NI 
confirmed the presence of hypoxia in NCI-H1975s as reported earlier by PISTOL 
imaging. The baseline and therapy induced characteristics of hypoxia of both the PDX 
tumor models were studied via PISTOL as well as GdDO3NI. M112004 tumors were 
more hypoxic, had more intra-tumor heterogeneity and higher edema fraction than 
M1005 pre-treatment (i.e. baseline characteristics). The post-TPZ treatment reduction in 
the oxygenation in M1005 tumor centers might be due to the vascular disruptive nature of 
TPZ. We observed a decrease in oxygenation but also an increase in the regions with 
hypoxia in M1005 tumors post TPZ therapy. The TPZ-induced changes in oxygenation of 
NCI-H1975 tumors, where it was able to slow down the tumor growth, proved the anti-
angiogenic property of TPZ, which was in agreement with the previous studies that show 
tirapazamine causes vascular shutdown in the center of the tumor [188-190].  
The response of  NCI-H1975, A431, M1005 and M112004 tumors to TPZ 
revealed that an effective HAP needs to have higher hypoxic threshold, ability to 
penetrate into the more dense and hypoxic regions of the tumor (potentially containing 
the cells with more aggressive phenotype) and exert a good bystander effect. 
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The clinical performance of HAPs has been unsatisfactory. With the inclusion of 
a hypoxia imaging technique for stratification of patients, the outcome of the drug trials 
can be improved. The response of our tumor models to HAPs has highlighted the 
importance of assessing nitroreductase levels, cytotoxicity of the drug, sensitivity of the 
tumor models to the drug, ability of the drug to kill high-proliferating as well as non-
proliferating cells, drug penetration and bystander effect. As discussed before, hypoxia 
although present in most tumors is not always treatment limiting and it is important to 
differentiate the treatment limiting regions for predicting the therapeutic efficacy of 
HAPs. It is important to include the analysis of all the above mentioned factors in 
assessing the efficacy of a novel HAP in different pre-clinical as well as clinical tumor 
models for improving the clinical translatability of the drugs.  
The pre-clinical screening of novel therapeutic drugs is critical in predicting their 
efficacy in clinical trials. An efficient model for screening the HAPs should not only have 
the clinically relevant mutations and also correctly representation of the clinical tumor’s 
vasculature and hypoxia. The tumor vasculature is fundamentally different from the host 
tissue’s vasculature in structure, function and organization [23, 32]. Initially the tumor 
coopts the vasculature of surrounding tissue and initiates angiogenesis as the tumor grade 
increases [228, 229]. The occurrence of hypoxia is correlated with the pattern of 
vasculature and vice a versa, thus hypoxia and tumor vasculature both are important 
parameters in tumor’s growth [230-234]. Recent studies have shown that the location and 
microenvironment of the tumor defines the pattern of vasculature and hypoxia and in turn 
the response of tumor to targeted therapies [226, 235]. The incidence of hypoxia is 
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intertwined with the tumor’s microenvironment, thus it is important to screen the efficacy 
of hypoxia activated therapeutics within in-vivo models that show more clinically 
relevant representation of hypoxia. PDX models are a better platform than the established 
cell-line based models due to their ability to maintain the original characteristics of the 
parent clinical tumor. 
The subcutaneous tumors, especially of lung cancer models, are prone to be more 
hypoxic and necrotic due to the lack of vasculature that is found in orthotopic lung cancer 
tumors [30]. They also lack the interface between the host tissue and tumor that exists 
between the orthotopic tumors. The interface of the subcutaneous tumors with fat, muscle 
and connective tissue found beneath the skin contributes towards variation from the 
clinical tumors. Thus, incorporation of orthotopic models of NSCLC for evaluation of 
their baseline oxygenation and response to HAPs via our oximetry techniques should 
yield more clinically relevant results.  
In chapter 4 I was able to show the efficacy in reporting hypoxia by combined 
application of PISTOL and GdDO3NI imaging. The direct injection of HMDSO into the 
tumors allows us to measure the oxygenation of regions that might be perfusion limited 
and thus not able to be reported by GdDO3NI. Similarly, HMDSO droplets cannot be 
injected over the entire region of the tumors while GdDO3NI can be used to generate 3D 
maps of hypoxia. For the clinical translation of PISTOL, it is necessary to develop a 
nano-emulsion based platform for the systemic delivery of HMDSO or other siloxane 
based reporter molecules. Currently, the oxygenation information via PISTOL is limited 
to single slice, and implementation of spectral spatial pulses could allow for mult-slice or 
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3D acquisition of PISTOL maps. Extensive studies have been conducted on the PET 
hypoxia imaging agent 
18
F-FMISO or 
18
F-FAZA and a correlation analysis of GdDO3NI 
with the PET could be helpful in evaluating the clinical translatability of the MR agent.  
I also reported the correlation between the hypoxic maps obtained via GdDO3NI 
and immunohistochemical staining with pimonidazole. Visually, the hypoxia distribution 
pattern correlates between the pimonidazole images and GdDO3NI contrast enhancement 
maps obtained and highlight the agent’s ability to effectively report regions of hypoxia. 
Further modifications in the comparative analysis have potential to improve the 
correlation results between GdDO3NI and pimonidazole hypoxia maps. 
The cancer imaging community could be positively impacted by the availability 
of two new imaging techniques (one PISTOL and one contrast agent) for imaging tumor 
hypoxia. Thus this work could impact the broader medical research community by 
opening a new window into the progression of metastatic diseases. The techniques can be 
incorporated into routine examination of hypoxia in tumors as they undergo treatments in 
order to determine the window of opportunity at which the HAPs will be able to result in 
better treatment outcome. The imaging techniques could also be used to monitor the 
response of tumors towards the therapies and accordingly modify the treatment plan and 
dosage. The HAPs have been in development since the past 40 years and yet no single 
agent has been approved for clinical use. Our techniques have the potential to improve 
the outcome of clinical results involving HAPs by allowing the clinicians to extract 
quantitative as well as qualitative distribution and severity of hypoxia within the tumors. 
The information can be used to formulate the therapy protocol that will result in the 
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maximum impact. The administration of HAPs as a single therapy is unlikely and 
combination therapeutic protocols involving HAPs is the future. The goal of combination 
therapeutics would be to ensure the eradication of hypoxic as well as the normoxic 
fraction of the tumors. Administration of HAPs with conventional therapies and guided 
with hypoxia imaging techniques for patient selection has the potential to significantly 
improve the treatment outcome and clinical translation of HAPs. The combination 
therapies can be designed based on the mechanism of action of drugs e.g. cytotoxic drugs 
such as TPZ and TH302 could be administered in combination with radiotherapies and 
chemotherapies which are inhibited by the hypoxia mediated resistance. The combination 
therapy of PR509 with anti-angiogenic drugs such as cyclophosphamide could increase 
the regions that will be affected by PR509 as cyclophosphamide would facilitate the 
increase in hypoxia. PR509 could also be administered with chemotherapies such as 
cisplatin and docetaxel that are cytotoxic and target the highly proliferative cells in the 
tumor. The dosing and schedule of the therapies would be dependent on the mechanism 
of action of the drugs being administered. Anti-angiogenic drugs could be administered 
first to increase the regions with hypoxia followed by administration of HAPs.  Thus the 
imaging techniques could impact future patients by aiding the design and development of 
personalized therapy (e.g. patient stratification for novel hypoxia activated pro-drugs) 
particularly for cancer and by the potential to improve how radiotherapy is planned and 
delivered in the clinic. 
Possible Future Experimentation: The imaging protocol for generation of 
oxygenation maps using PISTOL were acquired at a time interval of 5 days, although 
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smaller intervals of 2 to 3 days could be incorporated into future studies for evaluating of 
oxygenation changes at early time points post administration of therapy. The acquisition 
of T1-weighted images at a higher temporal resolution (< 15 s) up to 15 minutes post-
injection of GdDO3NI agent could facilitate the determination of parameters such as 
volume transfer constant (K
trans
), extravascular and extracellular volume fraction (ve) and 
the rates of transfer of contrast agent (CA) etc using a three compartment model [236-
238]. The length of the post-injection scan time can be increased to, say, 180 min from 
130 min to evaluate the time course behavior of hypoxic and normoxic regions at later 
time points. The goal of increasing the number of T1-weighted scans post-injection would 
be to achieve a complete clearance of the contrast agent from normoxic regions and 
analysis of concentration of the agent in hypoxic regions at those time points. The 3D 
gradient echo images provide a 3D distribution of the regions with hypoxia and can be 
used to calculate the hypoxic fraction of the entire tumor volume. Future studies could 
also focus on evaluating the binding efficiency of GdDO3NI at various levels of hypoxia 
as they can used for extracting quantitative oxygenation data. Immunohistochemical 
staining for multiple hypoxic markers such as HIF1α along with pimonidazole could 
provide information regarding the regulation of hypoxia in tumors. Future studies could 
also involve the staining for tumor vasculature and angiogenesis related markers for 
evaluation of tumor perfusion and regulation of angiogenesis. The inclusion of ex-vivo 
staining for proliferation markers in tumors would be useful for evaluating the treatment 
effect involving HAPs.  The therapy protocol for this study consisted of a single dosage 
of HAPs and future studies could evaluate the effect of multiple dosages (such as at 
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intervals of 5 days) of the agents on tumor volume and oxygenation. The dosing time 
interval could be decided based on the imaging protocol. The effect of combination 
therapies such as HAPs with cyclophosphamide (anti-angiogenic drug), cisplatin or 
chemo radiation could be exploited in future studies.  
Experimental Challenges: The oxygenation data obtained using PISTOL 
technique is dependent on the distribution of neat HMDSO in the tumors. The goal is to 
have a uniform distribution of HMDSO droplets thoughout the tumor. The physical 
properties of each tumor model affect the ability of the experimenter to distribute the 
probe uniformly. For example, a tumor with higher structural integrity and high 
interstitial pressure would show higher resistance which might result in difficulty in 
depositing the HMSO in tumor centers, while a tumor with higher edema or fluid fraction 
would facilitate an easier injection of the probe. Multiple droplets (~ 2 µl in volume) 
should be deposited at equal distance as the needle is pulled of the tumor. HMDSO is 
hydrophobic thus care needs to be taken when injecting the probe so that it does not enter 
the blood stream and cause an embolismin the mouse. The challenges involved with 
GdDO3NI imaging protocol include the intravenous injection of the contrast agent. The 
agent should be injected steadily and slowly in order to make a successful injection. It is 
important to maintain the animals at a stable temperature and respiration rate to facilitate 
correct evaluation of tumor perfusion. The correlation of pimonidazole staining tumor 
sections with the corresponding MR images is dependent on maintaining the same 
orientation of the extracted tumor between the cryosectioning and MR image acquisition. 
External markers can be drawn over the tumor as the tumor is placed over the mouse bed 
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for imaging and those markers can be used as a guide to orient to the tumor when placing 
in OCT for cryosectioning.  
In conclusion, the techniques discussed in this thesis have a great potential for 
translation into the clinic. The field of hypoxia activated therapies is still evolving and 
inclusion of these techniques could improve the translatability of the drugs. Our imaging 
techniques could be exploited for validation of predictive biomarkers in patient 
subpopulation as well as studying the treatment response (e.g. the modifications in 
hypoxic fraction). Personalized medicine is an emerging paradigm and these techniques 
have the potential in facilitating development of personalized therapeutic protocol by 
detecting the hypoxic biomarkers at various stages of treatment course. The incorporation 
of these techniques in routine examination of hypoxia behavior of the tumor could also 
shed more light on the role of hypoxia in treatment outcome and disease progression.  
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A.1 ABSTRACT 
We have previously reported the ability of HMDSO and HMDSO based nano-
emulsions for accurate and repeated measurements of oxygen using the PISTOL 
technique. In this study, we report the feasibility of linear siloxanes hexadimethylsiloxane 
(HMDSO) octamethyltrisiloxane, (OMTSO) and polydimethylsiloxane (PDMSO) 
oxygen reporter molecules. The spin-lattice relaxation rate of all the siloxanes exhibited a 
linear relationship with the oxygenation (R1 versus pO2): R1 (s
-1
) = 0.1105 ± 0011*pO2, 
0.1497 ± 0.0013*pO2 and 0.2091 ± 0.0012*pO2 at 7 T and 37 ºC for neat HMDSO, 
OMTSO and PDMSO respectively.  The sensitivity index decreased with an increase in 
chain length and the values ranged from 7.5 – 11.5 X10-3 torr-1. We observed no 
substantial change in the relaxation time at higher magnetic fields for HMDSO and 
OMTSO, thus indicating no substantial increase in imaging time. A small temperature 
dependence (approximately 1-2 torr/ ºC) in the calibration curves for HMDSO, OMTSO 
and PDMSO at higher magnetic fields was observed, similar to the previous report on 
neat HMDSO at 4.7 T. In summary, we have demonstrated the feasibility of various 
linear and cyclic siloxanes as pO2-sensing probes for 
1
H MR oximetry. 
A.2 Introduction 
The 
19
F NMR oximetry uses exogenous perfluorocarbon reporters such as perfluoro-15-
crown-5-ether (15C5[145]) as oxygen reporters. FREDOM (Fluorocarbon Relaxometry 
using Echo planar imaging for Dynamic Oxygen Mapping) is a technique that exploits 
the linear relationship of hexafluorobenzene (HFB) with oxygenation. Our group has 
previously shown the feasibility of accurate and repeated measurements of oxygen using 
HFB and hexamethyldisiloxane  (HMDSO) in thigh and tumor regions in-vivo using the 
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19
F
 
and
 1
H NMR spectroscopy and imaging based sequences [141, 239-241] respectively. 
We have also shown the ability of HMDSO based nano-emulsions for tissue oximetry 
[146]. In this study, we have further characterized the calibration curves of various linear 
siloxanes and their utility as pO2 sensing reporter molecules. The siloxanes characterized 
in this study are: linear siloxanes hexamethyldisiloxane, octamethyltrisiloxane (OMTSO), 
and polydimethylsiloxane (PDMSO, trimethylsiloxy terminated, M.W. 410) at 7 T.   
  
A.3 Materials & methods 
 
Preparation of siloxane samples for R1 calibration  
The linear siloxanes hexamethyldisiloxane (HMDSO), octamethyltrisiloxane 
(OMTSO), and polydimethylsiloxane (PDMSO) were purchased from Sigma-Aldrich (St. 
Louis, MO). All the materials were used as received.  
For the sample preparation, each siloxane was placed in 4 gas-tight NMR glass 
tubes (Wilmad Taperlok 528SJH, Buena, NJ) and saturated by bubbling for 15 minutes 
with varying standard of gases including 0%, 5%, 10%, and 21% O2 (balance N2), 
respectively. Gases with varying oxygen concentrations were made by mixing nitrogen 
and air in varying proportions in a HypoxyDial™ (STARR Life Sciences Corp.; 
Oakmont, PA, USA). A pO2 meter was connected in line with the output of the 
HypoxyDial™ in order to verify the accuracy of the HypoxyDial™. The tubes were then 
sealed. For measurement of the temperature dependence of T1, the temperature of the 
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water pad was varied between 17 to 52 
o
C. A fiber optic probe (FISO Technologies Inc., 
Quebec, Canada) was used to measure the temperature of the tubes. 
MRI experiments were performed on a Bruker BioSpec 7 T horizontal bore 
system equipped with actively shielded gradients. The tubes were placed together on a 
pad with circulating water and imaged using a volume transceiver coil [146]. At all the 
magnetic field strengths T1 was measured as a function of temperature in the 
physiologically relevant range of 17-52 
o
C. T1 measurements were performed after the 
tube temperature was allowed to equilibrate at the desired value for 10-20 min.  
Pulse sequence for measuring pO2 
A frequency selective 
1
H NMR spectroscopy based sequence as described in 
detail in reference [140] was used for determination of T1 of the prepared samples at 4.7 
T. A 
1
H MR spin-echo imaging based sequence as described in detail in reference [141] 
and an inversion recovery based sequence was used for T1 determination at 7 T. T1 data 
were fit to a single exponential, 3-parameter saturation-recovery equation (refer to 
equation [1]) using the Levenberg-Marquardt algorithm. The data at each temperature 
was then fit into the equations 1-3 to obtain the corresponding calibration constants and 
T1 values.  
                                                          R1 = A' + B' ∗ pO2                                               [1] 
Where, A’ is the diamagnetic i.e. anoxic component and B’ is the paramagnetic 
component that is dependent on pO2.  
The temperature dependence of the A’ and B’ components can be approximated 
as: 
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A' =  A + C ∗ T  
                                                           B' =  B + D ∗ T                                                  [2] 
Thus, a temperature dependent model for estimation of pO2 can be obtained by 
substituting the values from equation 1.8 in equation 1.7. 
                                         R1 = A + B ∗ pO2 + C ∗ T + D ∗ T ∗ pO2                            [3] 
The above equation can be used to determine oxygenation levels as well as errors 
in estimation pO2/°C, thus providing a more accurate and reliable quantification. The 
following equation can be used to determine error in pO2 determination for change in 
temperature by 1°C at a particular temperature T and oxygenation level: 
 
∆pO2
∆T
=
|C + D∗pO2|
B + D∗T
         [4] 
 
Calculation of error in pO2 determination 
Using the characterization parameters A, B, C, D, the relative errors in the pO2 
determination were calculated at all the field strength using equation [4] for oxygenation 
levels in relevant a hypoxic range (0 Torr to 50 Torr) at 37°C and for a change in 
temperature by 1°C.  
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A.4 Results 
 
Calibration of HMDSO at 7 T  
The calibration of HMDSO was conducted at 7 T to study the effect of variation 
of pO2 and temperature on R1 of HMDSO. R1 values were obtained as a function of pO2 
while the temperature was kept constant. The acquired R1 vs. temperature data was fit to 
the linear model described before to yield the calibration constants A’ and B’ at 7 T 
(figure A.1). The R1 of the HMDSO showed a linear dependence with the pO2 at a fixed 
temperature.  
A’ and B’ were then plotted with respect to variations in temperature, in the 
physiologically relevant range of 17°C to 48°C, to yield characterization parameters A, B 
C and D at 7 T (figure A.1 C & D). For pO2 of 5 Torr, the resulting error in pO2 
determination for a change in temperature by 1°C at 37°C was ~ 0.1 Torr/°C at 7 T. 
 
 
 
 
 
 
 
148 
 
Table A.1: Calibration constants of HMDSO at 7 T and 9.4 T. 
η
 (
X
1
0
-3
) 
=
B
’/
A
’ 
9
.7
 
1
1
.3
3
 
S
lo
p
e 
B
’ 
(s
*
to
rr
)-
1
 
3
7
°C
 
0
.0
0
1
0
8
 ±
 
1
.7
x
1
0
-5
 
 
0
.0
0
1
2
 ±
 
8
.8
1
x
1
0
-6
 
 
In
te
rc
ep
t 
A
’ 
(s
-1
) 
3
7
°C
 
0
.1
1
0
5
6
 ±
 
6
.5
4
x
1
0
-4
 
 
0
.1
1
0
6
8
4
2
5
 
 
D
 
(s
*
T
o
rr
*
°C
)
-1
 
-9
.4
4
E
-0
6
 ±
 
8
.8
7
 x
 1
0
-7
 
 
-7
.7
5
E
-0
6
 ±
 
3
.5
 x
 1
0
-7
 
C
 (
s*
°C
)-
1
 
-0
.0
0
1
0
3
 ±
 
4
.1
4
 x
 1
0
-5
 
 
-0
.0
0
1
4
 ±
 
1
.7
7
 x
 1
0
-5
 
B
 (
s*
T
o
rr
)-
1
 
0
.0
0
1
4
 ±
 
3
.0
9
 x
 1
0
-5
 
0
.0
0
1
5
 ±
 
8
.1
7
 x
 1
0
-6
 
A
 (
s-
1
) 
0
.1
5
  
±
 2
 x
 
1
0
-3
 
0
.1
6
2
1
 ±
 
3
.4
5
 x
 1
0
-4
 
M
ag
n
et
ic
 
fi
el
d
 
st
re
n
g
th
 
7
 T
 
9
.4
 T
 
149 
 
 
Figure A.1: Neat HMDSO R1 dependence on pO2 at different temperatures at 7 T. 
 
Calibration of Octamethyltrisiloxane (OMTSO) at 7 T 
OMTSO is a symmetric molecule with a single NMR resonance close to that of 
tetramethylsilane (TMS). OMTSO has characteristics similar to that of HMDSO and its 
R1 showed a linear dependence on pO2. Calibration of OMTSO was done at 7 T and the 
acquired R1 vs. temperature data was fit to the linear model described before to yield the 
calibration constants A’ and B’. 
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The temperature dependence of constants A’ and B’ was determined by linear 
fitting the constants at different temperatures at  7 T. The error in pO2 determination for 
a1°C change in temperature was calculated to be ~ 1 Torr/°C for a pO2 of 5 Torr at 7 T. 
 
Figure A.2: Neat OMTSO R1 dependence on pO2 at different temperatures at 7 T 
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Table A.2: Calibration constants of OMTSO at 4.7 T, 7 T and 9.4 T. 
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Calibration of polydimethylsiloxane at 7 T 
PDMSO (M.W. 410) is a polymer of dimethylsiloxane with a viscosity of 2 
centistokes. The temperature dependence of constants A’ and B’ was determined by 
linear fitting the constants at different temperatures at 7 T (figure A.3). At 7 T the values 
were A= 0.29023 ± 0.0036 s-1, C=-0.0022 ± 9.53x10-5 (s*°C)-1 (figure A.3 C) and 
B=0.0015 ± 3.13x10
-5
 (s*Torr)
-1
 and D= -8.61x10
-6 
± 8.22x10
-7
 (s*Torr*°C)
-1
 (figure A.3 
D). The error in pO2 determination for a 1°C change in temperature was calculated to be 
~ 1.9 Torr/°C for a pO2 of 5 Torr at 7 T (figure A.4 C). 
 
Figure A.3: Neat PDMSO R1 dependence on pO2 at 7 T. 
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Table A.3: Calibration constants of PDMSO at 7 T. 
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Figure A.4: The comparison of simulated error in pO2 determination for neat (A) 
HMDSO, (B) OMTSO and (C) PDMSO with a 1
o
C change in temperature in a hypoxia 
relevant pO2 range at 37
o
C at 4.7, 7 and 9.4 T. 
 
A.5 Discussion 
Accurate assessment of oxygenation is vital for monitoring tissue and organ 
functions and also for the diagnosis and characteristization of pathophysiology. PISTOL 
has been established as a quantitative oximetry technique that allows for accurate, non-
invasive and repeated measurement of tissue oxygenation. HMDSO has been 
characterized as the oxygen reporter agent and HMDSO based nanoemulsions have also 
shown their ability to report oxygenation in-vivo at 4.7 T [146]. Measuring tissue 
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oxygenation using siloxanes at higher magnetic field strength has the following 
advantages: 1) species have larger chemical shift separation between them which aids in 
selective excitation, 2) increase in net magnetization (M0 ∝ B0). It is well known that at 
higher magnetic fields the relaxation time gets longer (for small molecules) which might 
result in an increase in the total imaging time [242, 243]. Our goal was to evaluate the 
relationship of T1s of HMDSO and OMTSO at 7 T and 9.4 T and also help in 
determining the choice of siloxane (smaller dynamic range of T1’s across the pO2 range) 
for applications requiring faster time resolution. Our results suggest that for neat 
HMDSO at 7 T, T1 at 37°C ranged from 9 seconds (pO2=0 Torr) to 3.5 seconds (pO2=160 
Torr) and at 9.4 T, T1 ranged from 9 seconds (pO2=0 Torr) to 3.21 seconds (pO2=160 
Torr) which differed by ~ 2 % from T1 obtained at 4.7 T [140] indicating no substantial 
increase in imaging time. Also, the calculated error in pO2 determination as given by 
Equation [8] at 37°C for 1°C change in temperature was ~ 0.1 Torr/°C at 7 T and ~ 1.18 
Torr/°C at 9.4 T when the actual pO2 value was 5 Torr. Since the imaging time at 7 T and 
9.4 T was same as for 4.7 T with no significant increase of error in pO2 determination, 
imaging of HMDSO would be desired at higher magnetic field strengths. Similarly for 
OMTSO the T1 ranged from 6.4 seconds at 4.7 T to 6.7 seconds at 7 T and 7 seconds at 
9.4 T (pO2=0 Torr) and from 2.1 seconds at 4.7 T to 2.7 at 7 T and 2.6 seconds at 9.4 T 
(pO2=160 Torr). Thus, the changes in the T1 did not result in a substantial increase in the 
imaging time for OMTSO.  
The calibration of OMTSO and PDMSO demonstrated that longitudinal 
relaxation rate of both the siloxanes varied linearly with respect to changes in pO2, 
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demonstrating the potential of OMTSO and PDMSO to measure dynamic changes in 
tissue pO2 following intramuscular injection.  At a constant temperature of 37°C OMTSO 
(B’OMTSO@4.7 T = 0.0013 ± 2.66x10
-5, B’OMTSO@7 T = 0.0013 ± 5.55x10
-5, B’OMTSO@9.4 T = 
0.0014 ± 8.66x10
-5
) and PDMSO (B’PDMSO@7 T = 0.0012± 1.59x10
-5
) had oxygen 
sensitivity similar to HMDSO (B’HMDSO@4.7 T = 0.0013 ± 5.5x10
-5, B’HMDSO@7 T = 0.00108 
± 1.7x10
-5, B’HMDSO@9.4 T =0.0012 ± 8.81x10
-6
). Another important observation was that 
PDMSO had higher anoxic relaxation rate (A’) compared to neat HMDSO at 7 T and 
OMTSO at 7 T. OMTSO also had higher anoxic relaxation rate (A’) compared to neat 
HMDSO at 4.7 T, 7 T and 9.4 T respectively. The higher anoxic relaxation rate indicates 
faster T1 for the siloxanes which can be further exploited to map tissue oxygenation faster 
than HMDSO. It should be also noted that the boiling point of neat OMTSO (153°C) is 
higher than the boiling point of neat HMDSO (101°C) and neat PDMSO (85-105 °C) 
thus OMTSO is advantageous for the emulsification process as it would be less volatile 
during the emulsification process [244]. The errors in pO2 determination for OMTSO as 
well as PDMSO were found to be in the same range as HMDSO at 4.7 T, 7 T and 9.4 T 
respectively at an actual pO2 of 5 Torr with change in temperature by 1°C at 37°C. Thus, 
OMTSO and PDMSO can be identified as a promising pO2 probe which could enable 
faster mapping of tissue oxygenation than HMDSO. Alternatively, for applications 
requiring faster time resolution, one can use cyclic or long chain linear siloxanes as the 
reporter molecules because of their smaller dynamic range of T1s. 
As stated before, at a given temperature (and magnetic field) the linear 
relationship between pO2 and temperature (defined by equation [4]) determines the 
157 
 
sensitivity of R1 to changes in pO2. The ratio η = slope/intercept (B’/A’) is a parameter 
that helps in determining the sensitivity index of different MRI pO2 reporter molecules. A 
larger slope and smaller intercept represents greater sensitivity to changes in pO2 but also 
indicates longer imaging times. We observed a decrease in η with respect to an increase 
in chain length of the linear siloxanes and the η values ranged from 7.5 – 11.5 X10-3 torr-
1
. 
The octanol-water partition coefficient (KOW) defines the hydrophobicity and 
lipophilicity of a compound and a higher KOW represents higher hydrophobicity [245]. 
The octanol-water partition coefficient of HMDSO is 4.2 [245], octamethyltrisiloxane is 
4.8[245], decamethyltetrasiloxane is 5.4 [245], dodecamethylpentasiloxane is 6 [245], 
octamethylcyclotetrasiloxane (OMCTSO) is 6.98 [246] and 
decamethylcyclopentasiloxane (DMCPSO) is 8.09 [246] at ~ 25 ºC.  As evident, the 
hydrophobicity of organic siloxanes increases with increasing molecular weight.  
Our previous studies have shown the feasibility of measuring oxygenation via 
direct injection of siloxanes into the region of interest. The direct injection of neat 
siloxane or nano-emulsions ensures the delivery of a sufficient dosage of the probe over 
the entire tissue or tumor, although this method of delivering the reporter agent is limited 
to regions that are accessible. Siloxane based nano-emulsions with systemic deliverability 
needs to be developed in order to map the oxygenation of inaccessible regions. Various 
HMDSO based oil in water nanoemulsions have been synthesized successfully using 
PEGylated non-ionic surfactant and have been characterized with respect to changes in 
pO2 and temperature [146, 247]. These nanoemulsions have oxygen sensitivity similar to 
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neat HMDSO indicating potential of and being used as a pO2 probes following systemic 
delivery. 
In summary, we have demonstrated for the first time the feasibility of various 
linear and cyclic siloxanes as pO2-sensing probes for 
1
H MR oximetry. These siloxanes 
of different chain lengths with a broad range of boiling points, hydrophobicity and 
dynamic range of T1s can be used for diversifying the application of 
1
H MR oximetry. 
With systemic delivery for tissue oximetry in mind, we plan to further synthesize 
siloxane based nano-emulsions and optimize the synthesis procedure to obtain smaller 
sized nanoprobes, which could improve uptake in regions with restricted vascularization 
and reduce the bias in delivery to well vascularized regions as has been seen with the use 
of microemulsions [248].  
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1. Permission to reproduce and modify Figure 1.2 A 
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